[COMPANY_001] Research and Development
AMG334
Clinical Trial Protocol CAMG334A2401 / [STUDY_ID_REMOVED]
A 12-month prospectiv e, randomized, inter ventional, 
global, multi -center, activ e-controlled study
 comparing 
sustained benefit of tw o treatment paradigms (erenumab 
qm vs. oral prophy lactics) in adult epi[INVESTIGATOR_348126]: Amended Protocol Version
EUDRACT number: 2018 -001228 -20
Version number: 02(Clean)
Clinical Trial Phase: IV
Release date: 15-Jun-2020
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
Clinical Trial Protocol Template version 1.0 dated 01- Dec-2017

[COMPANY_001] Confidential Page 2
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Table of contents
Table of contents ................................................................................................................. [ADDRESS_432484] of abbreviations ............................................................................................................ 6
Glossary  of terms ................................................................................................................. 8
Amendment 02 ......................................................................................................................... 10
Amendment 01 ......................................................................................................................... 13
Protocol summary .............................................................................................................. 15
1Introduction ....................................................................................................................... 19
1.1 Background ............................................................................................................ 19
1.2 Purpose .................................................................................................................. 20
2Objectives and endpoints ................................................................................................... 21
3Study  design ...................................................................................................................... 23
4Rationale ............................................................................................................................ 26
4.1 Rationale for stud y design ................................ ................................ ..................... 26
4.2 Rationale for dose/regimen and duration of treatment .......................................... 26
4.3 Rationale for choice of control drugs (comparator) .............................................. 27
4.4 Purpose and timing of interim anal yses/design adaptation s
.................................. 28
4.5 Risks and benefits .................................................................................................. 28
5Population .......................................................................................................................... 29
5.1 Inclusion criteria .................................................................................................... 29
5.2 Exclusion criteria ................................................................................................... 30
6Treatment ........................................................................................................................... 33
6.1 Study  treatment ...................................................................................................... 33
6.1.1 Investigational and control drugs .......................................................... 33
6.1.2 Additional study  treatments .................................................................. 33
6.1.3 Treatment arms/group ........................................................................... 33
6.1.4 Treatment duration ................................................................................ 34
6.2 Other treatment(s) .................................................................................................. [ADDRESS_432485] numbering ................................................................................ 35
6.3.2 Treatment assignment, randomization .................................................. 35

[COMPANY_001] Confidential Page 3
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
6.[ADDRESS_432486] demographics/other baseline characteristics............................................. 45
8.3 Efficacy .................................................................................................................. 45
8.3.1 Migraine day s
........................................................................................ 46
8.3.2 Appropriateness of efficacy  assessments .............................................. 46
8.4 Safety ..................................................................................................................... 47
8.4.1 Laboratory  evaluations .......................................................................... 48
8.4.2 Electrocardiogram (ECG) ..................................................................... 48
8.4.3 Pregnancy .............................................................................................. 49
8.4.4 Appropriateness of safety  measurements .............................................. 49
8.5
Additional assessments.......................................................................................... 49
8.5.1 Clinical Outcome Assessments (COAs) ............................................... [ADDRESS_432487] -study  treatment .......................................................... 56
10Safety  monitoring and reporting ................................ ................................ ........................ 56

[COMPANY_001] Confidential Page 4
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
10.1 Definition of adverse events and reporting requirements ...................................... 56
10.1.1 Adverse events ...................................................................................... 56
10.1.2 Serious adverse events .......................................................................... 58
10.1.3 SAE reporting
........................................................................................ 58
10.1.4 Pregnancy  reporting .............................................................................. 59
10.1.5 Reporting of stud y treatment errors including misuse/abuse ................ [ADDRESS_432488] demographics and other baseline characteristics...................................... 63
12.3 Treatments ............................................................................................................. 63
12.4 Analy sis of the primary  endpoint(s) ...................................................................... 64
12.4.1 Definition of primary  endpoint(s) ......................................................... 64
12.4.2 Statistical model, hy pothesis , and method of anal ysis.......................... 64
12.4.3 Handling of missing values/censoring/discontinuations ....................... 64
12.4.4 Sensitivity  and Supportive anal yses...................................................... 64
12.5 Analy sis of secondary  endpoints ........................................................................... 65
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s) .................................... 65
12.5.2 Safety  endpoints .................................................................................... 65
12.5.3 Pharmacokinetics .................................................................................. 66
12.5.4 DNA ...................................................................................................... 66
12.5.5 Biomarkers ............................................................................................ 66
12.5.6 PK/PD relationships .............................................................................. 66
66
67
12.7 Interim anal yses..................................................................................................... 67
12.8
Sample size calculation .......................................................................................... 67
12.8.1 Primary  endpoint(s) ............................................................................... 67
13Ethical consi derations and administrative procedures ................................ ...................... 67
13.1 Regulatory and ethical compliance ........................................................................ 67

[COMPANY_001] Confidential Page 5
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
13.2 Responsibilities of the investigator and IRB/ IEC................................ .................. 67
13.3 Publication of study  protocol and results ............................................................... 68
13.4 Quality  Control and Quality  Assurance ................................................................. 68
14Protocol adherence ............................................................................................................ 68
14.1 Protocol Amendments ........................................................................................... 69
15References ......................................................................................................................... 70
16Appendices ........................................................................................................................ 72
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs ......................... 72
16.2 Appendix 2: L iver event and Laboratory  trigger Definitions and Follow
-up 
Requirements ......................................................................................................... [ADDRESS_432489] of tables
Table 1
-1 Protocol Summary ................................................................................. 15
Table 2
-1 Objectives and related endpoints .......................................................... 21
Table 4
-1 Rationale for stud y design ..................................................................... 26
Table 6
-1 Investigational and control drug............................................................ 33
Table 6
-2 Prohibited medication ........................................................................... 35
Table 8
-1 Assessment Schedule – Core Phase ...................................................... 42
Table 8
-2 Assessment Schedule – Extension Phase .............................................. 44
Table 8
-3 Safety  Assessments ............................................................................... 47
Table 10
-1 Guidance for capturing the study  treatment errors includi ng 
misuse/abuse ......................................................................................... [ADDRESS_432490] of figures
Figure 3 -1 Study  Design Schematic ....................................................................... 25

[COMPANY_001] Confidential Page 6
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
List of abbreviations
γ-GT Gamma -glutam yl transferase
AE adverse event
AESI adverse event of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analysis of covariance
AST aspartate aminotransferase
b.i.d. twice a day
BMI Body Mass Index
BUN blood urea nitrogen
C-SSRS Colum bia Suicide Severity Rating Scale
CD-ROM compact disc –read only memory
CDS Core Data Sheet (for marketed drugs)
CFR Code of Federal Regulation
CK creatinine kinase
CO 2 carbon dioxide
COAR Clinical Operations, Analytics & Regions
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CTC Common Toxicity Criteria
CTRD Clinical Trial Results Database
CV coefficient of variation
DMC Data Monitoring Committee
EC Ethics committee
ECG Electrocardiogram
EDC Electronic Data Capture
ELISA Enzy me-linked immunosorbent assay
eSAE Electronic Serious Adverse Event
FDA Food and Drug Administration
GCP Good Clinical Practice
h hour
HIV human immunodeficiency virus
i.v. intravenous
ICH International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
IRB Institutional Review Board
IRT Interactive Response Technology

[COMPANY_001] Confidential Page 7
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
LDH lactate dehydrogenase
LFT Liver function test
LLN lower limit of normal
LLQ lower limit of quantification
MABEL minimum anticipated biological effect level
MedDRA Medical dictionary for regulatory activities
mg mi lligram (s)
mL mi lliliter(s)
ml mi lliliter(s)
MRSD maximum recommended starting dose
NCDS [COMPANY_001] Clinical Data Standards
NOVDD [COMPANY_001] Data Dictionar y
o.d. once a day
p.o. oral
PA posteroanterior
PD pharmacodynamic(s)
PIP pediatric investigation plan
PK pharmacokinetic(s)
PTA Post- trial access
RBC redblood cell(s)
RDC Remote Data Capture
REB Research Ethics Board
s.c. subcutaneous
SAE serious adverse event
sCR serum creatinine
SD standard deviation
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic py ruvic transaminase
SoC Standard of Care
SOM Site Operations Manual
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reactions
TBL total bilirubin
ULN upper limit of normal
ULQ upper limit of quantification
WBC white blood cell(s)
WHO World Health Organization

[COMPANY_001] Confidential Page 8
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_37214] A specific group of subjects fulfilling certain criteria
Control drug A study drug used as a comparator to reduce assessment bias, preserve 
blinding of investigational drug, assess internal study validity, and/or evaluate 
comparative effects of the investigational drug.
Control drug Any drug (an active drug or an inactive drug, such as a placebo) which is 
used as a comparator to the investigational drug being tested in the tr ial
Dosage Dose of the study treatment given to the subject in a time unit (e.g. 100 mg 
once a day, 75 mg twice a day)
Enrollment Point/time of subject entry into the study; the point at which informed consent 
must be obtained (i.e. prior to starting any of the procedures described in the 
protocol).
Enrollment Point/time of subject entry into the study at which informed consent must be 
obtained (i.e. prior to starting any of the procedures described in the protocol)
Epoch Interval of time in the planned conduct of a study. An epoch is associated 
with a purpose (e.g. screening, randomization, treatment), which applies 
across all arms of a study.
Healthy volunteer A person with no known significant health problems who volunteers to be a 
study participant 
Investigational drug The study drug whose properties are being tested in the study; this definition 
is consistent with US CFR 21 Section 312.3 and Directive 2001/20/EC and is 
synony mous with “investigational new drug” or “test substance”
Investigational drug The study drug whose properties are being tested in the study; this definition 
is consistent with US CFR 21 Section 312.3 and is s ynon ymous with 
“investigational new drug” or “investigational medicinal product”.
Investigational 
treatmentAll investi gational drug(s) whose properties are being tested in the study as 
well as their associated treatment controls. This includes any placebos, any 
active controls, as well as approved drugs used outside of their 
indication/approved dosage or tested in a fixed combination. Investigational 
treatment generally does not include other treatments administered as 
concomitant background therapy required or allowed by [CONTACT_331985]/dosage.
Medication number A unique identifier on th e label of each study drug package in studies that 
dispense study drug using an IRT sy stem.
Medication pack 
numberA unique identifier on the label of each drug package in studies that dispense 
study treatment using an IRT sy stem
Non-investigational 
medicinal Product 
(NIMP)Products which are not the object of investigation (e.g. any background 
therapy administered to each of the clinical trial subjects, regardless of 
randomization group, rescue medication, active drug run -ins etc.)
Part A single com ponent of a study which contains different objectives or 
populations within that single study. Common parts within a study are: a 
single dose part and a multiple dose part, or a part in patients with 
established disease and in those with newly -diagnosed di sease.
Patient An individual with the condition of interest
Period A minor subdivision of the study timeline; divides phases into smaller 
functional segments such as screening, baseline, titration, washout, etc.
Premature subject 
withdrawalPoint/time w hen the subject exits from the study prior to the planned 
completion of all study drug administration and assessments; at this time all 

[COMPANY_001] Confidential Page 9
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
study drug administration is discontinued and no further assessments are 
planned.
Randomization 
numberA unique identif ier assigned to each randomized subject, corresponding to a 
specific treatment arm assignment
Screen Failure A subject who is screened but is not treated or randomized
Stage A major subdivision of the study timeline; begins and ends with major study 
milestones such as enrollment, randomization, completion of treatment, etc.
Study com pletion Point/time at which the subject came in for a final evaluation visit or when 
study drug was discontinued whichever is later.
Study drug 
discontinuationPoint/tim e when subject permanently stops taking study drug for any reason; 
may or m ay not also be the point/time of premature subject withdrawal.
Study 
drug/treatmentAny drug (or combination of drugs) administered to the subject as part of the 
required study pro cedures; includes investigational drug, active drug run -ins 
or background therapy.
Study treatment Any drug administered to the study participants as part of the required study 
procedures; includes investigational drug (s), control(s) or non -investigation al 
medicinal product(s)
Study treatment 
discontinuationWhen the subject permanently stops taking study treatment prior to the 
defined study treatment completion date
Subject A trial participant (can be a healthy volunteer or a patient)
Subject An individual who has consented to participate in this study. The term 
Subject may be used to describe either a healthy volunteer or a patient.
Subject number A unique number assigned to each subject upon signing the informed 
consent. This number is the defi nitive, unique identifier for the subject and 
should be used to identify the subject throughout the study for all data 
collected, sample labels, etc.
Subject number A num ber assigned to each subject who enrolls in the study. When com bined 
with the center number, a unique identifier is created for each subject in the 
study.
Treatment number A unique identifier assigned in non- randomized studies to each dosed 
subject, corresponding to a specific treatment arm 
Variable Information used in the data analy sis; derived directly or indirectly from data 
collected using specified assessments at specified timepoints.
Variable A measured value or assessed response that is determined in specific 
assessments and used in data analysis to evaluate the drug being tested in 
the study
Withdrawal of 
consent (W oC)Withdrawal of consent from the study is defined as when a subject does not 
want to participate in the study any longer, anddoes not want any further 
visits or assessments, anddoes not want any further study rela ted contact, 
anddoes not allow analysis of already obtained biologic material

[COMPANY_001] Confidential Page 10
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Amendment [ADDRESS_432491] -Trial Access (PTA) to erenumab for eligible 
patients c ompleting visits through week 52 of the Core Phase .  Patient eligibility  will be 
determined by [CONTACT_348156][INVESTIGATOR_348127]: 1) patients treated with erenumab must have
benefited from erenumab treatment and2) patients on Standard of Care (SoC) oral proph ylactic 
must be in need of a treatment switch.  PTA to erenumab will be provided for up to 52 weeks
(based on continued benefit of erenumab treat ment) in all eligible patients.
The PTA -Open -Label Treatment Period (Extension Phase) will evaluate further long-term 
safet y and clinical benefit of erenumab. 
 
During the Extension Phase patients will be administered study  drug at the study  site at quarterly 
study  visits.  Between the quarterly visits patients will have study  drug injections ever y 28 days 
either 1) administered by [CONTACT_348157] 2) self-administered at 
home with documented on- site training for correct injection procedure .
In addition, details for potential trial conduct changes due to the COVID -[ADDRESS_432492] been made to the relevant protocol 
sections.
Changes to the protocol
Protocol Summa ry
Updated to add details for revised stud y design, removed Follow -up visit, clarified 
Exclusion criteria language for prohibited medications  
Section 3.0 Study  design
Added Core Phase text, removed Follow -Up visit ,provide ddetails for PTA -
Extension Phase with up dated Figure 3 -1and added details for CSR requirements.
Section 4.1 Rationale for study  design
Added rationale for PTA -Open -Label Treatment Period
Section 4.3 Rationale for choice of control drugs (comparator)
Deleted table describing SoC oral prophy lactic migraine drugs available.
Section 4.5 Risks and benefits
Added Investigators Brochure as a ref erence for risks and benefits
Section 5.2 Exclusion criteria
Revised Exclusion Criteria 5 and 8 for clarit y,removed text with reference to during 
treatment period throughout section as t his is not an exclusion criteria and updated 
Exclusion Criteria 18 for clarity .
Section 6.1 Study  treatment

[COMPANY_001] Confidential Page 11
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Revised Core Phase and added Extension Phase drug details in Table 6 -1, and added 
details for Extension Phase and Section 6.1.3 and Section 6.1.4 updated for clarity .
Section 6.2.2 Prohibited medication and Section 6. 2.3 Rescue medication
Updated prohibited medication section for clarit y and added details for rescue 
medication collection in eCRF pages.
Section 6.3.2 Treatment assignment, randomization
Updated details for Core Phase randomization and added Extension Phase details.
Section 6.6.1 Treatment Compliance
Added details for Core and Extension Phase
Section
6.7 Preparation and dispensation
Added guidance section for COVID -19 related to delivery  of study  drug and self -
administration of study  drug for patients a ffected by  [CONTACT_47098].
Section
[IP_ADDRESS] Handling of study  treatment
Added details for self -administration of study  drug.
Section 6.7.2 Instruction for prescribing and taking study  treatment
Added details for self -administration of study  drug and provided clarity  for dosing 
windows .
Section 7 Informed consent procedures
Updated to add guidance for COVID -
19 for signing of general informed consent 
documents and added details for patients that had self
-administration of study  drug 
and the require ments to sign an ICF to document the process.
Section 8 Visit schedule and assessments
Added details for Extension Phase in text, updated Core Phase text and assessment 
Table 8- 2 for Extension Phase assessments .Revised guidelines for dosing windows 
for clarit y and i ncluded a guidance section for COVID -19 related to alternatives for 
conducting stud y visits with options to use phone calls, virtual visits etc. for patients 
affected b y the pandemic. 
Section 8- 3 Eff icacy
Added guidance for COVID -19 that PRO scales may  still be collected by  [CONTACT_348158]  
Section 8.4 Safety
Included guidance for COVID -19 indi cating that regular phone or virtual calls would 
occur to monitor the safety  of patients impacted due to the pandemic and updated 
schedule for ph ysical exam .
Section 8.4.1 L aboratory  evaluations
Introduced guidance for COVID
-19 to indicate that collection of laboratory  samples 
may need to be modified for patients impacted due to the pandemic.
Section 8.4.3 Pregnancy

[COMPANY_001] Confidential Page 12
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Introduced guidance for COVID- 19 to indicate that urine pregnancy  tests may  be used 
at home instead of conducted in the clinic when serum or ur ine pregnancy  tests were 
scheduled for patients impacted due to the pandemic.
 
Section 9.1
Introduced additional rea sons for discontinuation of study  treatment during the
Extension Phase and added a section to provide clarity  for what occurs during the 
Core Phase when a patient discontinues the study .
Section 9.[ADDRESS_432493] -study  treatment
Provided details for Extension Phase
Section 12 Data analy sis and statistical methods
Provided details that Core and Extension phase data would be anal yzed separatel y.
Section 12.1 Analy sis sets
Introduced an anal ysis set for the Extension Phase.
Section 12.5.2 Saf ety endpoints
Provided details that safety  data collected during Extension Phase 
would be anal yzed 
separately and deleted summary  of AEs of special interest since analy sis is not 
conducted .
Section 13.3 Publication of study  protocol and results
Introduced details for clinical study  reports.
Section 16.2 Appendix 2: L iver event and Laboratory  trigger Definitions and Follow - up 
Requirements
Provided guidance in footnote to Table 16-[ADDRESS_432494] a 
liver event .
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities.
The changes described in this amended protocol are substantial and require IRB/IEC approval 
prior to implementation. 

[COMPANY_001] Confidential Page 13
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes described in this 
protocol amendment.
Amendment [ADDRESS_432495] feedback 
received from Health Authorities on contraception/pregnancy language and on standard of care 
practices globally  from participating investigators. Additionally , text was added to clarify 
protocol text language, t ypographical errors, and grammatical errors.  
Changes to the protocol
Protocol Summary
The Protocol Summary  was updated to reflect the updates made in the protocol 
below.
 
Section 3 Study  design
Clarified discrepancy  on study  completion and the Follow -up Visit that it should 
occur 16 weeks after the Week 52 visit
Section 5.1 I nclusion Criteria
Inclusion criterion 6 updated to align with exclusion criterion 4
Section 5.2 Exclusion Criteria
Exclusion criterion [ADDRESS_432496] guidance documents and investigator 
practice for prior treatment failures.  
Exclusion criterion 20 has been updated to include language related to highly 
effective met hods of contraception.
Section 6.1.1 I nvestigational and Control Drugs
Capsule was added as a possible formulation for oral proph ylactics.
Section 6.1.3 Treatment arms/groups
The stratification cap was re -iterated to provide better clarity .
Section 6.2.2 Prohibited Medication
Text table was updated to align with exclusion criterion 22
Section 6.5 Dose escalation and dose modification
Added statement clarify ing source documentation of dose changes
Section 6.6.1 Treatment compliance

[COMPANY_001] Confidential Page 14
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Clarified that documentat ion to be captured onl y in the source documents and drug 
accountability  log for standard of care
Table 8- 1 Assessment Schedule
Updated table to reflect amended protocol text
Section 8.3.1 Migraine day s
Added text on additional data points captured in the e Diary  related to vertigo and 
menses
Table 8
-3 Safety  Assessments
Clarified that height and weight will onl y be captured at full ph ysical exams
 
Section 10.1.1 Adverse Events
Clarified that adverse event collection should only begin at Treatment/Day 1 visit
Section 12.4 Analy sis of the primary  endpoint(s)
Clarified that the anal ysis is comparing to oral prophylactics
Section 12.5 Analy sis for the secondary  endpoints
Updated language to reflect updates to objectives and endpoints
Section 12.8 Sample size calculation
Clarified that the anal ysis is comparing to oral prophy
lactics

[COMPANY_001] Confidential Page 15
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Protocol summary
Table 1-1 Protocol Summary
Protocol 
numberAMG334A2401
Full Title A 12- month prospective, randomized, interventional, global, multi- center, active -
controlled study comparing sustained benefit of two treatment paradigms 
(erenumab qm vs. oral prophylactics) in adult epi[INVESTIGATOR_348128] &[COMPANY_010]
Phase IV
Investigation 
typeBiological
Study type Interventional
Purpose and 
rationaleThe purpose of this study is to compare the sustained long -term benefit between 
two treatment paradigms of migraine prophylactic agents (erenumab versus a 
control arm of oral prophylactics) in epi[INVESTIGATOR_348129] [ADDRESS_432497] previo usly failed existing preventative treatments, as there are limited 
treatment options. Subsequently it will determine if early use of erenumab during 
a treatment algorithm is associated with a favorable long -term sustained benefit.
The PTA -Open -Label Treatm ent Period will provide additional information for 
longer term safety  and will provide an assessment of effectiveness.
Primary 
Objective(s) The primary  objective is to demonstrate the superiority of subcutaneous 
erenumab compared to oral prophylactic(s) on sustained benefit defined as % 
subjects completing one- year on the randomized treatment and achieving at 
least a 50% reduction from baseline in monthly migraine days at month 12.
Secondary 
ObjectivesObjective 1: To evaluate the effect of erenumab comp ared to oral prophylactic(s) 
on overall subject retention defined as % subjects completing treatment period at 
Month 12 on initially assigned treatment
Objective 2: To evaluate the effect of erenum ab compared to oral prophylactic(s) 
on the change from  base line in monthly m igraine days during the treatment period
Objective 3: To evaluate the effect of erenum ab compared to oral prophylactic(s) 
onthe subject's assessment of the change in clinical status since the start of 
treatment as measured by [CONTACT_309575] ' Global Impression of Change (PGIC) Scale
Study design This study uses a single -cohort, 2 -treatment arm (erenumab versus SoC oral 
prophylactic treatment), parallel -group randomized (2:1 [erenumab (70 mg or 140
mg): SoC oral prophylactic]), open -label des ign in adult patients with epi[INVESTIGATOR_348130] 1 or 2 prophylactic migraine treatments. The 
following periods are included in the study design, with study visits at 4 -week 
intervals after completion of screening:
Screening Period (0 -2 weeks) –Required for all subjects to assess initial 
eligibility and to obtain informed consent

[COMPANY_001] Confidential Page 16
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Baseline Period (4 weeks) –All subjects successfully completing the 
Screening Period will be invited to participate. Eligibility for rand omization will 
be assessed based on migraine frequenc y and diar y compliance during this 
period. Randomization will be stratified by [CONTACT_348159] (due to insufficient efficacy or poor tolerability) 
reported during Screening/Baseline Period: 1 treatment failure (TF1) vs 2 
treatment failures (TF2). A cap of 30% randomized subjects to the TF2 strata 
will be implemented. The stratification and 30% cap will be implemented 
within IRT.
Open -Label Randomized Treatment Peri od (52 weeks) –All subjects 
successfully completing the Baseline Period will be invited to participate. 
Eligible subjects will be randomized 2:1 to one of two treatment arms 
[erenumab s.c. q.m. versus SoC oral prophylactic (active comparator)]. Only 
monotherapy will be allowed in both arms and no concomitant use of other 
prophylactics for migraine specifically should be used. At the end of this 
period, the final assessment to address the effect of erenumab compared to 
SoC oral prophylactic c ycling on the net benefit and related objectives will 
occur. The last dose for erenumab will occur at W eek 48 (monthly dose) and 
the last dose for SoC will occur at Week 52. 
Switching: Treatment (failure) status and decision on whether or not to 
switch to a new treatment will be check ed at ever y visit and will be 
based on investigator and subject discretion (based on 
efficacy /tolerability/satisfaction but not based on pre- specified cutoffs for 
certain parameters). In both arms, switching will be allowed within 
approved prophylactics in the respective country for prophylaxis of 
migraine.
PTA-Open -Label Treatment Period (52 Weeks) –Patients completing visits 
through week 52 of the Core Phase will be eligible to participate.  Patient 
eligibility will be determined by [CONTACT_348156] [INVESTIGATOR_348127]: 1) 
patients treated with erenumab must have benefited from erenumab 
treatment and 2) patients on Standard of Care (SoC) oral prophylactic must 
be in need of a treatment switch. PTA to erenumab will be provided for up to 
52 weeks (based on continued benefit of erenumab treatment) in all eligible 
patients; this will ensure erenumab access until country -level launch and 
subsequent reimbursement decision in all countries .
Should a trea tment gap exist between the Core and Extension Phase due to
a delay of HA/EC approvals or other administrative/logistical reasons, the 
subject may  enter the PTA-Open -Label Treatment Period at a later time. 
During this treatment gap the patient would remain in the ma in study  and is 
allowed to be treated with any medication as deemed appropriate by [CONTACT_348160]’s migraines . Upon HA and EC approval of 
the PTA -Open -Label Treatment Period, the patient will then be administered 
study drug correspondi ng to the Week 52 dose and will continue dosing 
every 4 weeks as per protocol .  Patients will be required to follow all protocol 
requirements for treatments allowed and for prohibited medications ( Section 
6.2.2 ).
End of Trial will occur when the last subject com pletes their last visit (LPLV) of 
the study . A final study  report will be prepared and finalized for all data after 
all subjects have completed their respective last visit (LPLV).
Population The study population wil l consist of adult male and female subjects with a 
documented history of epi[INVESTIGATOR_17730] (4 to 14 baseline migraine days), who 
have failed 1 or 2 previous migraine prophylactic treatments for lack of efficacy  or 

[COMPANY_001] Confidential Page 17
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
tolerability. The goal is to randomize approximately 600 subjects in approximately 
100 centers worldwide.
Key Inclusion 
criteriaAdults ≥18 of age upon entry into screening.
Documented history of migraine (with or without aura) ≥12 months prior to 
screening.
≥4 and <15 days per month of migraine symptoms (based on ICHD- 3 criteria) 
on average across 3 months prior to screening based on retrospective 
reporting.
<15 days per month of headache s ymptoms (i.e., migraine and non- migraine)
Subjects in need for switching by [CONTACT_348161] [ADDRESS_432498] 6 months due to either lack of efficacy or poor tolerability 
(see list of prophylactic therapi[INVESTIGATOR_348131] 6 and definition for 
lack of efficacy  and poor tolerability). For subjects with [ADDRESS_432499] 6 months.
During baseline period, confirmed migraine frequency of 4 to 14 migraine 
days and <15 days of headache sy mptoms.
During baseline period, ≥80% compliance with the headache diar y.
Key Exclusion 
criteriaOlder than 50 years of age at migraine onset.
Lack of efficacy or poor tolerability with > 2 treatments from the following 7 
medication categories for prophylactic treatment of migraine after an 
adequate therapeutic trial. These medication categories are:
Category 1: Divalproex sodium, sodium valproate
Category 2: Topi[INVESTIGATOR_348132] 3: Beta blockers (for example: atenolol, bisoprolol, metoprolol, 
nadolol, nebivolol, pi[INVESTIGATOR_8405], propranolol, timolol)
Category 4: Tricy clic antidepressants (for example: amitriptyline, 
nortriptyline, protriptyline)
Category 5: Serotonin -norepi[INVESTIGATOR_5608] (for example: 
venlafaxine, desvenlafaxine, duloxetine, milnacipran)
Category 6: Flunarizine, verapamil
Category 7: Lisinopril, candesartan
Efficacy  failure is defined as no meaningful reduction in headache 
frequency, duration, and/or severity after administration of the 
medication for at least 6 weeks at the generally accepted therapeutic 
dose(s) based on the investigator’s assessment. 
Tolerability failure is defined as documented discontinuation due to adverse 
events of the respective medication during the last 6 months prior to 
screening
The following scenarios do not constitute lack of therapeutic response :
Lack of sustained response to a medication
Patient decision to halt treatment due to improvement 
Used a prohibited medication from the 7 categories of prior prophylactic 
medications within 3 months prior to the start of and during baseline for a 
non-migraine indication if dose is not stable.
Device, or procedure that potentially may interfere with the intensity  or 
number of migraine day swithin 2 months prior to the start of or during 
baseline.

[COMPANY_001] Confidential Page 18
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Exposure to botulinum toxin in the head and/or neck region within 4 months 
prior to the start of the baseline period, during the baseline period
Taken the following for any indication in any month during the 2 months prior 
to the start of the baseline period: 
Ergotamines or triptans on ≥ 10 days per month, or
Simple analgesics (non -steroidal anti -inflammatory  drugs [NSAIDs], 
acetaminophen) on ≥ 15 days per month, or
Opi[INVESTIGATOR_2480] -or butalbital -containing analgesics on ≥4 day s per month.
Previous exposure to erenumab or exposure to any other prophylactic 
CGRP -targeted therapy.
Study 
treatmentErenumab (70 mg or 140 mg) in 70 mg/1mL pre -filled syringes
Locally approved oral prophylactics
Efficacy 
assessmentsMigraine days
Patient study co mpletion
Key safety 
assessmentsAdverse events
Physical examinations
Laboratory evaluations
ECG
Other 
assessmentsPatient Reported Outcomes (PROs)
Patients' Global Impression of Change (PGIC)
 
Data analysis The primary  analyses will compare the proportion of subjects who achieve a net 
benefit between erenumab vs oral prophylactics. A Cochran -Mantel -Haenszel 
(CMH) test stratified by [CONTACT_348162] (1 vs. 2) will be 
used under a 2 -sided significance level of 0.05 to evaluate the association 
between the net benefit rate and the treatment.
The secondary analy sis will be handled as such:
Proportion of subjects completing the st udy at month -12 on the randomized 
treatment 
This variable will be analyze same as that of the primary analy sis.
Global satisfaction as measured by [CONTACT_348163] 12 as per randomized 
treatment 
Patient will be considered as responder if PGI -I score is 5, 6, or 7. 
Proportion of responders based on PGI- I score at month 12 will be 
analyzed same as that of the primary  endpoint.
Cumulative average change from baseline on the monthly migraine days 
during the treatment period (month 1 -12) 
The average of monthly migraine days will be obtained cumulatively at 
each month across 12 months. The cumulative average change from 

[COMPANY_001] Confidential Page 19
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
baseline on the monthly migraine days will be derived using difference 
between cumulative average at each month and baseline monthly 
migraine day s. The change from baseline will be analyzed using a linear 
mixed effects model including treatment group, baseline value, 
stratification factor(s), scheduled visit, and the interaction of treatment 
group with scheduled visit.
Key words Erenumab, AMG334, migraine, epi[INVESTIGATOR_49564], headache, CGRP
[ADDRESS_432500] common neurological disorders with a high global prevalence, 
significant socio -economic burden and substantial impairment and disability  of affected 
patients ( 2017). It is mainly  characterized by [CONTACT_348164] 4-[ADDRESS_432501] increase with higher attack frequency , which 
is why the spectrum of migraine disorders is typi[INVESTIGATOR_348133]. “Epi[INVESTIGATOR_17730]” (EM) is characterized by [CONTACT_348165] 
14 migraine days per months, while “Chronic migraine” (CM) is defined as [ADDRESS_432502] to be t ypi[INVESTIGATOR_238933].
Migraine patients are currently  being treated prophy lactically  by a variety of drug classes, 
many 
of them being used off-label and often based on insufficient or limited evidence. Common 
prophy lactic drugs or drug classes used include beta-blockers, anti-epi[INVESTIGATOR_125796] (including 
topi[INVESTIGATOR_348134]), antidepressants (mainly  amitripty line and venlafaxine), certai n 
calcium channel blockers (such as flunarizine and verapamil), and certain angiotensin-
converting -enzyme inhibitor/angiotensin II receptor blockers (ACE/ARBs such as lisinopril and 
candesartan). Botulinum toxin (Botox®) is approved in US and the majority  of the EU countries 
for CM use, but not for EM.
All of these therapi[INVESTIGATOR_348135]/or 
substantial tolerability  issues that often leads to treatment discontinuation in migraine patients. 
For example, in a recent claims database analysis in chronic migraine, persistence of oral 
prophy lactics at one year, irrespective of class, was as low as 13-16% (Hepp et al2016 ), 
therefore reflecting a high unmet medical need for new therapi[INVESTIGATOR_014]. The standard of care also 
varies significantl y across different geographies and treatment decisions are often made on a 
case-by-
case basis without consensus on treatment guidelines.
Based on emerging evidence, calcitonin gene -related peptide (CGRP) is a neuropeptide that 
prominently  contributes to migraine pathoph ysiology . The potential mechanisms of action of 
CGRP receptor antagonists involve components of the trigeminal -neurovascular system and 
include normalization of CGRP -induced vasodilation, r eduction of CGRP -induced neurogenic 
inflammation, and inhibition of pain transmission at the trigeminal ganglion and trigeminal 
nucleus (Wang et al 1995 , Zimmermann et al 1996, Durham 2006). The CGRP pathway  was an 
attractive target for the development of a migraine - specific proph ylactic therapy  with the aim 
of minimizing migraine days and improving patient quality  of life in this common and often 
disabling disorder.

[COMPANY_001] Confidential Page 20
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Erenumab (AMG334) is a monoclonal antibody  targeting the CGRP receptor, that is 
administered once monthly  via subcutaneous injection. Erenumab was approved by [CONTACT_348166] 17 May 2018 and EMA on 26 July  2018 for migraine prevention with an approved monthly 
dose of 70mg or 140mg. The benefits and safet y of Aimovig were studied in four clinical trials 
involving >2600 patients and has been shown to be an effective and well- tolerated treatment 
for both epi[INVESTIGATOR_49564] (Goadsb yet al2017 , Study  20120296) and chronic migraine 
(Tepper et al 2017, Study 20120295). Results were consistently  robust across different studies 
and different subgroups of patients, including patient groups with 
high unmet need such as those 
who have failed one or more prior prophy lactic therapi[INVESTIGATOR_348136] .
The initial phase 2 dose finding study  in epi[INVESTIGATOR_17730] (Sunet al 2016 , Study  20120178) 
included an ongoing 5-year open -label extension phase. In a pre- specified interim analy sis after 
all ongoing patients have completed one year of treatment, sustained efficacy  has been shown 
with a long-lasting reduction from baseline of approximately  5
 monthly  migraine days and with 
65% of patients achieving a 50% responder rate in the last month (Ashina et al 2017). Other 
recentl y available longer -term data after one year from studies [ADDRESS_432503] 
also confirmed that the retention remains high (75 -80% range at one year) and that the efficac y 
with continued erenumab treatment is sustained over time.
No active comparator studies were conducted in the pi[INVESTIGATOR_176241]. With all existing standard
of care treatments, no clearl y defined, evidence -based and commonl y accepted treatment 
algorithms exist. Choice of a treatment is heterogeneous across geographies and highl y 
dependent on both individual experience of the treating physician as well as particular patient 
profiles. Due to the low persistence of oral prophy lactics, switches between therapi[INVESTIGATOR_348137] -term disease control, particularl y as many 
therapi[INVESTIGATOR_348138].
Given the emerging erenumab clinical profile including the available data in treatment failure 
patients, one key question is if early use of erenumab during a treatment algorithm is associated 
with a favorable long-term sustained benefit and how erenumab compares with oral 
prophy lactics o ver one year in a real world setting.
1.2 Purpose
The purpose of this study is to compare the sustained long -term benefit between two treatment 
paradigms of migraine prophy lactic agents (erenumab versus a control arm 
of oral prophy lactics) 
in epi[INVESTIGATOR_348139] y failed [ADDRESS_432504] previousl y failed existing preventative treatments, as there are limited treatment options. 
Subsequently  it will determine if early use of erenumab during a treatment algorithm is 
associated with a favorable long -term sustained benefit.

[COMPANY_001] Confidential Page 21
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
2 Objectives and endpoints
Table 2-1 Objectives and related endpoints
Objective(s) Endpoint(s)
Primary objective(s) Endpoint(s) for primary objective(s)
To demonstrate the superiority of subcutaneous 
erenumab compared to oral prophylactics on 
sustained benefit defined as % subjects 
completing one- year on the randomized 
treatment and achieving at least a 50% reduction 
from baseline in monthly migraine days at month
12.Proportion of subjects who complete 
initially assigned treatment and achieve 
at least 50% reduction from baseline in 
monthly m igraine days at Month 12
Secondary objective(s) Endpoint(s) for secondary objective(s)
To evaluate the effect of erenumab compar ed to 
oral prophylactics on overall subject retention 
defined as % subjects completing treatment 
period at Month 12 on initially assigned treatmentProportion of subjects completing the 
treatment period at Month 12 on the 
initially assigned treatment
To evaluate the effect of erenumab compared to 
oral prophylactics on the change from baseline in 
monthly m igraine days during the treatment 
periodCumulative average change from 
baseline on the monthly migraine days 
during the treatment period for subjects
onthe initially assigned treatment 
(Months 1 -12)
To evaluate the effect of erenumab compared to 
oral prophylactics on the subject's assessment of 
the change in clinical status since the start of 
treatment as measured by [CONTACT_309575]' Global 
Impression of C hange (PGIC) ScaleProportion of responders (PGI-I score 
≥5)as measured by [CONTACT_348163]12 
for sub jects completing the treatment 
period at Month 12 on initially assigned 
treatment

[COMPANY_001] Confidential Page 22
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401

[COMPANY_001] Confidential Page 23
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
3 Study  design
This study  uses a single -cohort, 2-treatment arm (erenumab versus SoC oral prophy lactic 
treatment), parallel
-group randomized (2:1 [erenumab (70 mg or 140 mg): SoC oral 
prophy lactic]), open -label design in adult patients with epi[INVESTIGATOR_348140] y 
failed 1 or 2 prophy lactic migraine treatments. The following periods are included in the study 
design, with stud y visits at 4- week intervals after completion of screening:
Core Phase:
Screening Period (0 -2 weeks) – Required for all subjects to assess initial eligibility  and to 
obtain informed consent
Baseline Period (4 weeks) – All subjects successfully  completing the Screening Period 
will be invited to participa te. Eligibility  for randomization will be assessed based on 
migraine frequency  and diary  compliance during this period. Randomization will be 
stratified by  [CONTACT_348167] (due to insufficient 
efficacy  or poor toler ability ) reported during Screening/Baseline Period: 1 treatment 
failure (TF1) vs 2 treatment failures (TF2). A 30% cap of randomized subjects to the TF2 
strata will be implemented. The stratification and 30% cap will be implemented within 
IRT.
Open -Label R andomized Treatment Period (52 weeks) –All subjects successfull y 
completing the Baseline Period will be invited to participate. Eligible subjects will be 
randomized 2:1 to one of two treatment arms [erenumab s.c. q.m. versus SoC oral 
prophy lactic (active comparator)]. Onl y monotherapy will be allowed in both arms and no 
concomitant use of other prophy lactics for migraine specifically  should be used. At the 
end of this period, the final assessment to address the effect of erenumab compared to SoC 
oral proph ylactic cy cling on the net benefit and related objectives will occur. The last dose 
for erenumab will occur at Week 48 (monthly  dose) and the last dose for SoC will occur at 
Week 52. 
Switching: Treatment (failure) status and decision on whether or not to switch to a 
new treatment will be checked at every  visit and will be based on investigator and 

[COMPANY_001] Confidential Page 24
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
subject discretion (based on efficacy /tolerabilit y/satisfaction but not based on pre -
specified cutoffs for certain parameters). In both arms, switching will be a llowed 
within approved proph ylactics in the respective country  for prophy laxis of migraine.
Extension Phase
Post-Trial Access Open -Label Treatment Period (52 weeks) - Patients completing 
visits through week 52 of the Core Phase will be eligible to particip ate.  Patient eligibility  
will be determined b y the investigators opi[INVESTIGATOR_348127]: 1) patients treated with
erenumab must have benefited from erenumab treatment and 2) patients on Standard of 
Care (SoC) oral proph ylactic must be in need of a treatment s witch. PTA to erenumab will 
be provided for up to 52 weeks (based on continued benefit of erenumab treatment) in all 
eligible patients; this will ensure erenumab access until country -level launch and 
subsequent reimbursement decision in all countries.
Shou ld a treatment gap exist between the Core and Extension Phase due to a delay of 
HA/EC approvals or other administrative/logistical reasons, the subject may enter the 
Extension Phase at a later time. During this treatment gap, the patient would remain in the 
main study  and is allowed to be treated with an y medication as deemed appropriate b y the 
investigator to manage the patient’s migraines. Upon HA and EC approval of the 
Extension Phase , the patient will then be administered study  drug corresponding to the 
Week 52 dose and will continue dosing every  4 weeks as per protocol.  Patients will be 
required to follow all protocol requirements for treatments allowed and for prohibited 
medications ( Section 6.2.2 ).
End of Trial will occur when the last subject completes their last visit (L PLV) of the study .
Note: Treatment discontinuation does not imply  study  discontinuation. Every  effort should be 
attempted to ensure subjects complete the study  visits e vent if treatment is discontinued. After 
study  completion, post-trial access to erenumab will be offered to the study  participants as 
needed.
The primary  analysis will occur when the last patient completes the Core Phase, prior to the end 
of the Extension Phase . Themain study  report will be prepared and finalized at this time for all 
data from the Core Phase.
An additional study  report will be prepared for the Extension Phase after all patients have 
completed their respective last visit (L PLV)of the Exte nsion Phase and will report data for the 
Extension Phase .

[COMPANY_001] Confidential Page 25
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Figure [ADDRESS_432505] s complete the study visits even
if treatment is discontinued.
3Stratification based on Prior prophylactic migraine treatment - 1 prior treatment failure (70%) vs 2 prior treatment 
failures (30% c ap)
4 “Eligible Core Phase Completers” are patients that complete visits through Week 52 on or off of study drug and 
are either benefitting from erenumab treatment or are in need of a treatment switch .  

[COMPANY_001] Confidential Page 26
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
[ADDRESS_432506] Rationale
Overall (parallel, cross -
over, sequential, factorial)This will be a parallel study design. During the developmen t 
program placebo -controlled studies only were conducted. This 
study will provide data on erenumab's efficacy  and safety when 
compared head -to-head to SoC oral prophylactics. 
Randomization (strata, 
allocation ratio)Eligible subjects will be randomized 2:1 to one of two treatment 
arms (erenumab versus SoC oral prophylactic(s)) and will be 
stratified by [CONTACT_348167] 
(due to efficacy  or tolerability): 1 treatment failure (TF1) vs 2 
treatment failures (TF2) with a cap of 30% to the TF2 strata.
Unequal randomization favoring the erenumab treatment arm is 
expected to facilitate recruitment, generate additional data on TF1 
to complement previous studies on TF2, and to determine if early 
use of erenumab during the treatment algorithm is associated with 
a favorable long -term sustained benefit.
This randomization will allow for additional long -term efficacy  and 
safety data on erenumab
Open -label during core 
phaseGiven the difference in treatments (injectable vs. varied oral 
treatments), adequate blinding will not be possible. 
PTA-Open-L abel Treatment 
PeriodThe PTA-Open-L abel T reatment Period is a mechanism to provide 
52 weeks of PTAof erenumab for patients who completed visits 
through Week 52 of the Core Phase (see Section 3.0 for details)
4.2 Rationale for dose/regimen and duration of treatment
In order to capture real world, dose/regimen will follow the approved label. After regulatory 
review, erenumab was approved b y FDA and EMA as a monthl y treatment. The recommended 
dose is [ADDRESS_432507] with either 
70mg or 140 mg. Dose modification/escalation will be allowed as per the approved label. 
Treatment and an y modification should be documented. Data supporting the proposed regimen 
is described below.
Registration and elective clinical trials demonstrate that erenumab is safe and effective across 
the epi[INVESTIGATOR_17730] (EM) / chronic migraine (CM) spectrum, even in patients with prior 
preventive treatment failures (PPTFs) and medication overuse. (Goadsb yet al 2017, 
Dodick et
al2018, Tepper et al 2017, Reuter et al 2018 , Tepper et al 2017, Goadsb yet al2017, 
Ashina et
al2017)
Despi[INVESTIGATOR_348141], results were largel y similar across the 70 mg and 140 mg 
doses in the general trial population in terms of:
Primary  efficacy  endpoints: 

[COMPANY_001] Confidential Page 27
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Patients across the EM –CM spectrum who received erenumab (vs placebo) achieved 
significantl y greater reductions in monthly  migraine day  (MMD) frequency  
(Goadsb yet
al2017, Dodick et al 2018, Tepper et al 2017)
Both the 70 mg and 140 mg doses were superior to placebo in terms of reducing MM 
(Goadsb yet
al2017, Dodick et al 2018, Tepper et al 2017)
For patients with EM, a numericall y greater reduction in MMD was observed with 
140 mg compared with 70 mg ( Goadsby [CONTACT_348168]2017 )
Safety  and tolerability  profiles, as no dos e-dependent adverse events were observed 
(Goadsb yet al 2017, Tepper et al 2017, Data onFile, [COMPANY_010] )
However, the 140 mg dose demonstrated numer ically  improved results for:
All secondary
 endpoints, including the number of monthly  migraine day s (MMDs) and the 
 
(Goadsb yet al 2017, Dodick et al 2018, Tepper et al 2017)
Specific patient populations, e.g. patients with prior preventive treatment failures 
(Goadsb yet
al2017, Ashina et al 2017)
 
In the erenumab clinical program, about one third of patients have reported two or more PPTFs. 
In this patient segment of “difficult -to-treat” patients, erenumab achieved significant 
improvements in MMDs, 50% responders and  and demonstrated, safety  and and 
tolerability , supporting the use of 
erenumab in this population with a high unmet need. 
(Reuter et al 2018 )
Compared with the 70 mg dose, the 140 mg dose achieved numerically  greater improvements 
in MMDs in the PPTF subgroups assessed. Odds of achievin g ≥ 50% reduction in MMDs were 
numericall y greater for 140 mg versus 70 mg in both EM and CM studies, indicating that more 
“difficult -to-treat” patients can benefit from the 140 mg dose compared to the 70 mg dose. 
(Goad sby[CONTACT_2297] 2017, Ashina et al 2017 )
Varied standard of care treatments exist and switching among therapi[INVESTIGATOR_348142], which does 
not provide for long-term disease control. The duration of this study  will provide data on the 
long-term use of erenumab as compared to SoC oral proph ylactics.
4.3 Rationale for choice of control drugs (comparator)
Multiple oral prophy lactic treatments are approved and vary by [CONTACT_1606] .  A decision to use will 
be based on prior treatment failure opt ions and investigator decision. Only  monotherapy  will 
be allowed and switching treatment will be evaluated at every  visit and will be based on 
investigator and subject discretion. As these are approved and marketed therapi[INVESTIGATOR_014], these 
comparators must be used in accordance with the product label/package insert with the dosing 
captured in the source documents and eCRF. Medications not approved for migraine 
prophy laxis are not allowed as SoC. If at a visit a decision is made to switch treatment, the 
reason and n ew oral prophy lactic should be documented in the source and eCRF. 

[COMPANY_001] Confidential Page 28
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
4.4 Purpose and timing of interim analy ses/design adaptations
Not applicable
4.5 Risks and benefits
Key risks and benefits are briefl y summarized below. For further information, please refer to 
the current package insert/prescribing information and the Investigator Brochure .
As of June 2018, the safety  of erenumab in migraine prophy laxis was assessed from integrated 
safet y analyses of [ADDRESS_432508] -years (SY). Overall, the safet y and tolerability  profile 
of erenumab was similar between the 140 mg and 70 mg doses and comparable to placebo. 
Adverse drug reactions include injection site reactions, constipation, muscle spasms, and 
pruritus. The majority  were mild or moderate in severity  and rarely led to treatment 
discontinuation. To date, no important risk has been identified for erenumab.
Overall, to date, there is no evidence from non-clinical and clinical data of risk of cardiovascular 
effects. On the theoretical basis of the mechanism of action of erenumab, CGRP receptor 
blockade might reduce compensatory  vasodilation, particularly  under ischemic conditions. 
Therefore, cardiovascular effects continue to be monitored.
 
 
 
 
 
Plasma levels of CGRP increase with advancement of pregnancy  up to the time of delivery , 
followed by a
 sharp decline at term and postpartum in rats and humans. Endogenous CGRP 
may play an important role in maintaining normal fetoplacental development, fetal survival, 
and vascular adaptation during pregnancy . Women who are breastfeeding, pregnant, or 
planning to beco me pregnant are excluded from study participation, as well as patients who are 
unwilling to comply  with the protocol -specified contraception requirements. All women of 
child- bearing potential will be screened for pregnancy  at each study  visit.
An external data monitoring committee was established to review the erenumab safet y data for 
Phase 2b and Phase 3a studies, and based on these data, recommended continuation of the 
program. The need for a data monitoring committee (DMC) for this study was assessed, and 
deemed not necessary  because erenumab was approved by [CONTACT_348169] [ADDRESS_432509] been demonstrated in a Phase 2b 
trial ([COMPANY_010] Study  20120178), in which 70 mg was established as the minimally  effective dose 
in EM ( Sunet al 2016) with a significant placebo -corrected reduction of 1.1 monthly  migraine 

[COMPANY_001] Confidential Page 29
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
days compared to baseline, as well as positive results on most secondary  endpoints, including 
50% responder rate.
Three additional Phase 2/[ADDRESS_432510] established 70 mg and 140 mg as being effective and safe in patients 
with EM or CM, with a favorable benefit/risk profile. Positive treatment effects in general were 
observed in a robust way across typi[INVESTIGATOR_348143], > 50% (and higher) responder rates, change in migraine -specific medication use 
and functional improvement by [CONTACT_348170]. Results were in general highl y 
statistically  significant and clinically  meaningful. Retention rates observed in clinical trials 
were very  high (~95% with active treatment after 3 months and ~90% after 6 m onths with only 
minimal discontinuations attributed to adverse events). This feature is important, as 
discontinuation rates are high for current migraine prophy laxis treatments, with the main drivers 
of discontinuation being either lack of efficacy  or tolerability  issues (Blumenfeld et al 2013). 
As such, there is a high unmet need for a therapy  that is well -tolerated, has sustained response 
rates and excellent compliance.
As of July  2018, two open -label extension studies (OLE) of erenumab in patients with chronic 
(1 year) and epi[INVESTIGATOR_17730] (3 years) were reported confirming sustained efficacy  and a 
favorable safety  and tolerability  profile.
Overall, given the characteristics of erenumab and the large experience in clinical trials, the 
overall benefit -risk assessment is supportive.
[ADDRESS_432511] of adult male and female subjects with a documented history 
of epi[INVESTIGATOR_17730] (4 to 14 baseline migraine days), who have failed 1 or 2 previous migraine 
prophy lactic treatments for lack of efficacy  or tolerability .
The goal is to randomize approximately  600 subjects in approximately  100 centers worldwide. 
Assuming a 25% screen failure rate, approximately [ADDRESS_432512] meet allof the following criteria:
1.Written informed consent must be obtained before any  assessment is performed
2.Adults 
≥18 of age upon entry  into screening.
3.Documented history  of migraine (with or without aura) ≥[ADDRESS_432513] Edition (I CHD -3).
4.≥4 and <15 day s per month of migraine sy mptoms (based on ICHD -3 criteria) on average 
across 3 months prior to screening b
ased on retrospective reporting.
5.<15 day s per month of headache s ymptoms (i.e., migraine and non- migraine).
6.Subjects in need for switching b y documented failure of [ADDRESS_432514] 6 months due to either lack of efficacy  or poor t olerability (see list of prophy lactic 
categories in Exclusion Criteria 
4and definition for lack of efficacy  and poor tolerability ). 
For subjects with [ADDRESS_432515] 6 

[COMPANY_001] Confidential Page 30
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
months. For subjects with [ADDRESS_432516] 6 months.
7.During baseline: Confirmed migraine frequency  of 4 to 14 migraine day s and <15 day s of 
headache s ymptoms.
8.During baseline: ≥80% compliance with the headache diar y.
5.2 Exclusion criteria
Subjects meeting an y of the following criteria are not eligible for inclusion in this study .
1.Older than 50 years of age at migraine onset.
2.History  of cluster headache or hemiplegic migraine headache.
3.Unable to differentiate migraine f rom other headaches.
4.Lack of efficacy or poor tolerability  with > 2 treatments from the following 7 medication 
categories for proph ylactic treatment of migraine after an adequate therapeutic trial. These 
medication categories are:
Category  1: Divalproex sodium, sodium valproate
Category  2: Topi[INVESTIGATOR_052]
Category  3: Beta blockers (for example: atenolol, bisoprolol, metoprolol, nadolol, 
nebivolol, pi[INVESTIGATOR_8405], propranolol, timolol)
Category
 4: Tricy clic antidepressants (for example: amitripty line, nortript yline, 
protripty line)
Category  5: Serotonin-norepi[INVESTIGATOR_5608] (for example: venlafaxine, 
desvenlafaxine, duloxetine, milnacipran)
Category  6: Flunarizine, verapamil
Category  7: L isinopril, candesartan
Efficacy  failure is defined as no meaningful reduction in headache frequency , duration, 
and/or severit y after administration of the medication for at least 6 weeks at the 
generall yaccepted therapeutic dose(s) based on the investigator’s assessment.
Tolerability  failure is defined as documented disc ontinuati on due to adverse events of the 
respective medication during the last 6 months prior to screening
The following scenarios do not constitute lack of therapeutic response: 
-Lack of sustained response to a medication
-Patient decision to halt treatmen t due to improvement 
5.Used a prohibited medication from the 7 categories of prior proph ylactic medications 
within 3 months prior to the start of andduring baseline for a non-migraine indication if 
dose is not stable
6.Exposure to botulinum toxin in the head and/or neck region within 4 months prior to the 
start of the baseline period, during the baseline period.
7.Taken the following for any  indication in an y month during the 2 months prior to the start 
of the baseline period:
Ergotamines or triptans on ≥ 10 da ys per month, or

[COMPANY_001] Confidential Page 31
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Simple analgesics (non -steroidal anti -inflammatory  drugs [NSAIDs], acetaminophen) 
on ≥ 15 day s per month, or
Opi[INVESTIGATOR_2480] -or butalbital -
containing analgesics on ≥4 day s per month.
8. D evice, or procedure that potentially  may interfere with the intensity  or number of 
migraine day s within 2 months prior to the start of or during baseline. 
9.Active chronic pain syndromes (e.g., fibromyalgia, chronic pelvic pain).
10.History  of major ps ychiatric disorders (such as schizophrenia or bipolar disorder) or 
current evidence of depression. Subjects with anxiety  disorder and/or major depressive 
disorders are permitted in the study  if they  are considered by  [CONTACT_348171] [ADDRESS_432517] hav e been on a 
stable dose within the 3 months prior to the start of the baseline period.
11.History  of seizure disorder or other significant neurological conditions other than 
migraine. Note: a single childhood febrile seizure is not exclusionary .
12.History  of ma lignancy  of any  organ s ystem (other than localized basal cell carcinoma of 
the skin or in situ cervical cancer), treated or untreated, within the past 5 y ears, regardless 
of whether there is evidence of local recurrence or metastases.
13.Human immunodeficiency  virus (HIV) infection by  [CONTACT_969] .
14.History  or evidence of any  other unstable or clinically  significant medical condition that in 
the opi[INVESTIGATOR_155632] a risk to subject safet y or interfere with the 
study  evaluation, procedures, or completion.
15.Subject has an y clinically significant vital sign, laboratory , or electrocardiogram (ECG) 
abnormality  during screening that, in the opi[INVESTIGATOR_871], could pose a risk to 
subject safet y or interfere with the study  evaluat ion.
16.Myocardial infarction, stroke, transient ischemic attack, unstable angina, or coronary  
artery  by[CONTACT_348172] -vascularization procedures within 6 months prior to 
screening.
17.Score “y es” on item [ADDRESS_432518] 6 months, or “y es” on any  item of the Suicidal Behavior 
section, except for the “Non -Suicidal Self -Injurious Behavior” (item also included in the 
Suicidal Behavior section), if this behavior occurred in th e past [ADDRESS_432519] performed during screening (with the exception of prescribed medications 
or barbiturates).
19.Pregnant or nursing (lactating) women
20.Women of child- bearing potential, defined as all women physiologicall y capable of 
becoming pregnant, unless they  are using basic methods of contraception during dosing 
with study  treatment. The use of highl y effective methods of contraception are required 
for patients treated with oral proph ylactic medications that are contraindicated in women 
of child- bearing potential not using highl y effective contraception as per their loc al labels 
(e.g. topi[INVESTIGATOR_052], amitriptyline, beta- blockers). As topi[INVESTIGATOR_348144], another form of contraception (e.g. barrier method) must be used 

[COMPANY_001] Confidential Page 32
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
in addition to oral contraceptive. If treated with amitripty line, highl y effec tive methods 
should be used during treatment and continued for 30 day s after end of treatment
Highl y effective contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post -
ovulation methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total h ysterectom y or tubal ligation at least six weeks before 
taking investigational drug. In case of oophorectomy  alone, onl y when the 
reproductive status of the woman has been confirmed by [CONTACT_64062]
Male partner sterilization (at least 6 m prior to screening). The vasectomized 
male partner should be the sole partner for that subject
Use of oral, (estrogen and progesterone), injected or implanted hormonal 
methods of contraception or other forms of hormonal contraception that have 
comparable efficacy  (failure rate <1%), for example hormone vaginal ring or 
transdermal hormone contraception or placement of an intrauterine device (IUD) 
or intrauterine s ystem (IUS)
Basic contraception methods include:
All highly  effective methods listed above
Barrier methods of contracept ion: Condom or Occlusive cap (diaphragm or 
cervical/vault caps). For [LOCATION_006]: with spermicidal foam/gel/film/cream/ vaginal 
suppository
In case of use of oral contraception, women should have been stable on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_432520] 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(e.g. age appropriate, history  of vasomotor s ymptoms) or have had surgical bilat eral 
oophorectom y (with or without hy sterectomy ), total hy sterectom y or tubal ligation at least 
six weeks ago. In the case of oophorectomy  alone, only  when the reproductive status of 
the woman has been confirmed by  [CONTACT_50085].
21. Use of other investigational drugs within [ADDRESS_432521] has returned to baseline, whichever is longer.
22.History  of hypersensitivity  to any  of the study  drugs or its excipi[INVESTIGATOR_201014].
23.Previous exposure to erenumab or exposure to any  other prophy lactic CGRP -targeted 
therap y prior to the stud y.
No additional exclusions may be applied by [CONTACT_093], in order to ensure that the study  
population will be representative of all eligible subjects.

[COMPANY_001] Confidential Page 33
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
6 Treatment
6.1 Stud y treatment
6.1.1 Investigational and control drugs
Table 6-1 Investigational and control dru g
Investigational/ 
Control Drug
(Name [CONTACT_6673])Pharmaceutical 
Dosage FormRoute of 
AdministrationDescription Sponsor 
(global 
or local)
Core Phase
Treatment 
paradigm A: 
Erenumab (70
mg or 140 mg 
monthly) 
(AMG334)70mg/1mL pre -
filled syringesSubcutaneous Open label bulk supply. The 
70mg dose will be 
administered as 1mL dose 
from one sy ringe. The 140
mg dose will be administered 
as 2 syringes of 70 mg/mL. Sponsor 
global
Treatment 
paradigm B: 
Locally 
Approved SoC 
Oral 
Prophylactics 
(daily)Tablet /capsule Oral use Varies Local
Extension Phase
Treatment: 
Erenumab (70
mg or 140 mg 
monthly) 
(AMG334)70mg/1mL pre -
filled syringesSubcutaneous See above for erenumab Sponsor 
global
6.1.2 Additional study treatments
No additional treatment bey ond investigational drug and control drug are included in this trial.
6.1.3 Treatment arms/group
At the start of the Open -Label Randomized Treatment Period (Day  1)subjects will be assigned 
to either erenumab (70 mg or 140 mg) or SoC oral prophy lactic at the Treatme nt Visit in a 2:1 
ratio, 
stratified by [CONTACT_348173] (1 or 2 treatment 
failures due to efficacy or tolerability , with cap of 30% on 2 treatment failures ) reported durin g 
the Screening/Baseline Period. I n the erenumab arm, subjects may be treated with either 70 mg 
or 140mg based on the investigator's assessment. This information and reason for dose selection 
should be documented in the source and eCRF. Er enumab and SoC oral prophy lactics must be 
used in accordance with the locall y approved product label/package insert.
Study  medication will be:
Erenumab (labelled as AMG334): pre -filled 1mL  syringes (PFS) containing 70 mg/1mL  
of erenumab. 

[COMPANY_001] Confidential Page 34
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Comparator: local ly approved oral proph ylactic migraine medication.
Eligible subjects that complete the Core Phase (see Section 3.0 for eligibility  details) will be 
allowed to enter the Extension Phase and receive erenumab (70 mg or 140 mg).
6.1.4 Treatment duration
The planned duration of treatment is 52 weeks for the Core Phase . Subjects may be discontinued 
from treatment earlier due to unacceptable tolerability , lack of efficacy , and/or treatment is 
discontinued at the discretion of the investigato r or the subject, but encouraged to complete the 
subsequent study  visits.
Eligible subjects that complete the Core Phase (see Section 
3.0for eligibility  details ) will be 
allowed to enter theExtension Phase .The duration of the Extension Phase is 52 weeks from 
core phase study  completion atWeek 52(Week 52 through Week 104)
. During the Extension 
Phase subjects may be discontinued from treatment earlier due to unacceptable tolerability , lack 
of efficacy  and/or treatment may bediscontinued at the discretion 
of the investigator or the subject. Once a patient discontinues study drug the patient will 
complete a final stud y visit as described in Table 8-2.
6.2 Other treatment(s)
6.2.1 Concomitant therapy
All medications, procedures, and significant non-drug therapi[INVESTIGATOR_014] (including physical therap y and 
blood transfusions) administered after the patient was enrolled into the study  must be recorded 
in the concomitant medications / significant non- drug therapi[INVESTIGATOR_14932].
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt, the investigator should contact [CONTACT_18614] a subject or allowing a new medication to be started. If the subject is alread y 
enrolled, contact [CONTACT_331997] .
6.2.[ADDRESS_432522] is taking a migraine proph ylactic from the 7 categories of prior prophy lactic 
medications (Section 5.2) for a different pre -existing condition (not for migraine proph ylaxis), 
this will be allowed as long as the subject is on a stable dose for at least 3 months prior to 
baseline and the pre-existing condition and corresponding treatment is document edin the 
source and eCRF. 
Only  prophylactic migraine monotherap y is allowed during the study  in each arm (based on 
approved medications in each respective country for daily oral proph ylactic medications
). No 
other concomitant prophy lactics for migraine specificall y should be used, unless it is required 
by [CONTACT_348174]- titrate from one prophy lactic to another. 
Previously  taken failed prophy lactic treatment should not be re-introduced as a study  drug 
treatment .
Use of the treatments display ed in Table 6-2will NOT be allowed as designated due to the 
potential confounding of efficacy  assessments.

[COMPANY_001] Confidential Page 35
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Table 6-2 Prohibited medication
Medication Prohibition period Action taken
Botulinum toxin (in the head 
and/or neck region)Within 4 m onths of the start of 
the baseline period and 
throughout the studyDiscontinue study trea tment. 
Treatment discontinuation does 
not imply study discontinuation.
Devices or invasive 
interventions (e.g., nerve 
blocks, occipi[INVESTIGATOR_348145], transcranial 
magnetic stimulation)Within 2 month of the start of 
the baseline period and 
throughout the studyDiscontinue study treatment. 
Treatment discontinuation does 
not imply study discontinuation.
Other Calcitonin Gene -related 
Peptide (CGRP) antagonists
for migraine prophylaxisPrior to the start of the 
baseline period and throughout 
the studyDiscontinue study treatment. 
Treatment discontinuation does 
not imply study discontinuation.
6.2.3 Rescue medication
Subjects can continue to use “best supportive care" during the study . This can include both 
pharmacologic interventions (i.e., abortive treatments for acute attacks) and non-pharmacologic 
interventions (e.g., biofeedback, psychotherap y, acupuncture or other locally  accepted and 
endorsed interventions for migraine).
Site staff will pre -specify the name, dose strength, and route of administration of t
he subject’s 
acute headache (rescue) medications in the subject’s eDiary . If the subject takes an acute 
headache medication during aura or to treat a migraine or non-migraine headache, they will 
select one of the pre-
specified medications (or “other” medic ation) and enter the date of 
administration, the number of times the medication was taken on that date, and number of units 
taken.
During the Core Phase the use of rescue medication must only be recorded in the eDiary . During 
the Extension Phase the use ofrescue medications will be entered in the concomitant medication 
eCRF. Relevant non -drug therapi[INVESTIGATOR_348146] “best supportive care” use should be recorded in 
the eCRF.
6.[ADDRESS_432523] Number (Subject No.), that is assigned when 
the subject is first enrolled for screening and is retained as the primary identifier for the subject 
throughout his/her entire participation in the trial. The Subject No. consists of the Center 
Number (Center No.) assigned by [CONTACT_348175] a sequential subject 
number suffixed to it, so that each subject is numbered uniquel y across the entire database. 
Upon signing the informed consent form, the sub ject is assigned to the next sequential Subject 
No. available.
6.3.2 Treatment assignment, randomization
At Treatment Visit (Day 1 of Core Phase) , all eligible subjects will be randomized via 
Interactive Response Technology  (IRT) to one of the treatment arms. The investigator or his/her 
delegate will contact [CONTACT_201051]/exclusion 

[COMPANY_001] Confidential Page 36
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
criteria. Th e IRT will assign a randomization number to the subject, which will be used to link 
the subject to a treatment arm and will specify  a unique medication number for the first package 
of study  treatment to be dispensed to the subject.
The randomization number s will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from subjects and investigator staff. A subject 
randomization list will be produced by [CONTACT_6609] a validated system that automates 
the random assignment of subject numbers to randomization numbers. These randomization 
numbers are linked to the different treatment arms, which in turn are linked to medication 
numbers. A separate medication list will be produced by [CONTACT_348176] a validated system that automates the random assignment of 
medication numbers to packs containing the study treatment.
Randomization will be stratified b y prior proph ylactic migraine medication treatment failu re (1 
or 2 treatment failures due to efficacy  or tolerability ) reported during Screening/Baseline Period. 
The I RT will cap the randomization to the "2 prior treatment failure" strata to 30%.
The randomization scheme for subjects will be reviewed and approv ed by a m ember of the 
Randomization Office.
Patients that complete the Core Phase will be allowed to enter a 52 week Extension Phase (see 
Section 3.0 for details) .
6.[ADDRESS_432524] approved labelling and/or current standard of care and should be 
documented in the subjects source documents and in the eCRF . Investigator -initiated 
interruptions will be considered on a case -by-case basis.
6.5.[ADDRESS_432525] once a week (or more 
frequentl y if required by [CONTACT_15931], or if clinically  indicated) for [ADDRESS_432526]. Appropriate clinical experts should be consulted as deemed necessary .

[COMPANY_001] Confidential Page 37
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
6.[ADDRESS_432527]’s safety  and the validity  of the stud y. The subject must also be instructed to contact 
[CONTACT_087]/she is unable, for any reason, to take the study  treatme nt as prescribed. 
Compliance will be assessed by  [CONTACT_1755]/or study  personnel at each visit using pi[INVESTIGATOR_10705] (if applicable) and information provided by [CONTACT_423]. This information should be 
captured in the source document at each visit. SoC oral prophy lactics prescribed and used must 
be recorded in the Drug Accountability  Logfor Standard of Care, to allow proper 
reimbursement b y [COMPANY_001].
Extension Phase
After completion of the Core Phase (Week 52 Visit , Table 8-1) patients will be administered 
study  drug at the study  site(Week 52 Visit) and will then be required to have quarterl y study 
visits atthe study  site.  Between the quarterl y visits patients will have study  drug injections 
every  28 days either 1) administered by [CONTACT_348177] 
2) self-
administered at home with documented on-site training for correct injection procedure.
Note: If stud y drug is provided to the pat ient for self -administration, the patient will need to be 
properl y trained with required documentation filed in the patient’s source documents .  The 
documentation will need toindicate that the patient was trained on thecorrect injection 
procedure , the proper drug storage and required steps for document ing the injection details 
including day of injection, dose location etc. The patient will then need to provide the site with 
the required documentation at each quarterly visit.
6.6.2 Emergency  breaking of assigned treatment code
Not applicable as this is an open label stud y.
6.7 Preparation and dispensation
Each study site will be supplied with erenumab in packaging as described under investigational 
and control drugs section.
A unique medication number is printed on t he study  medication label.
Investigator staff will identify the stud y medication kits to dispense to the patient by [CONTACT_37246](s). The study medication has a 2 -part label (base 
plus tear-off label), immediately  before dispensing the medica tion kit to the patient, site 

[COMPANY_001] Confidential Page 38
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
personnel will detach the outer part of the label from the packaging and affix it to the source 
document.
During the COVID -19 pandemic that limits or prevents on -site study  visits, delivery  of study 
drug directl y to a particip ant’s home is generally permitted in the event the Investigator has 
decided that an on -site visit by  [CONTACT_348178], and that it is 
in the interest of the participant’s health to administer (e.g., self-injection or study staff 
administration at patients’ home) the study  treatment even without performing an on -site visit. 
Implementation will need to be discussed with [COMPANY_001] (see Section 7 for required training 
process). The dispatch of stud y drug from the site to the participant’s home remains under the 
accountability  of the Investigator. Each shipment/provisioning will be for a maximum of1
month supply . In this case, regular phone calls or virtual contacts (at the time of every  scheduled 
visit, or more frequently  if needed) will occur between the site and the participant for 
instructional purposes, safety  monitoring, and discussion of the participant´s health status until 
the participants can again visit the site.
6.7.1 Handling of study  treatmen t and additional treatment
[IP_ADDRESS] Handling of study  treatment
Erenumab must be received by  a designated person at the study  site, handled and stored safely 
and properl y and kept in a secured location to which only the investigator and designated site 
personnel ha ve access. During the Extension Phase erenumab may be provided to the patient at 
the quarterl y visits if the patient opts to self -administer study  medication at home .  For patients 
opting to self -administer study  medication at home documented trainingon the proper storage 
procedures is required . SoC oral proph ylactics will be sourced locally  and will be reimbursed 
by [CONTACT_1034]. Upon receipt, all study  treatment must be stored according to the instructions 
specified on the labels and in the prescribing information/package insert. Clinical supplies are 
to be dispensed only in accordance with the protocol. Technical complaints are to be reported 
to the respective [COMPANY_001] Country  Pharma Organization (CPO) Quality  Assurance.
Medication labels will be in the l ocal language and comply with the legal requirements of each 
country . They  will include storage conditions for the study  treatment but no information about 
the subject except for the medication number .
The investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability  log. Monitoring of drug accountability  will be performed by 
[CONTACT_30798]. Subjects will be asked 
to return all unused study treatment and packaging at the end of the study  or at the time of 
discontinuation of study  treatment.
At the conclusion of the study , and as appropriate during the course of the study , the investigator 
will return all unused study  treatment, packaging, drug labels, and a copy of the completed drug 
accountability  log to the [COMPANY_001] monitor or to the Sponsor address provided in the investigator 
folder at each site.
[IP_ADDRESS] Handling of additional treatment
Not applicable

[COMPANY_001] Confidential Page 39
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
6.7.2 Instruction for prescribing and taking study treatment
Refer to Section
6.1for information on the two treatment paradigms. Erenumab will be 
administered as a subcutaneous (sc) injection by [CONTACT_348179] . 
During Extension Phase subjects have the option toself-administer study  drug at home 
for drug dispensing visits after on-sitedocumented training) . For purposes of erenumab dosing, 
“qm” refers to a monthly injection regimen. Erenumab administration should occur at study 
visits (o
r drug dosing visits) and any dose administrations that may occur greater than +/- 5 days
from the 4 -week time point ( [ADDRESS_432528] dose administered; due to e.g., patient 
unavailability orscheduling conflicts) should be discussed with [COMPANY_001] prior to dosing. The 
anatomical sites for administration of erenumab are the upper arm, upper thigh, or abdomen; 
the location of the injection sites should be documented in the source document. For the 
comparator, the oral prophy lactics will be used according to the approved indication and 
package insert. Prescription of previous failed drugs is not allowed.
For subjects randomized to erenumab, injections will be administered by [CONTACT_348180] (i.e., Treatment Week 4, Week 8, through Week 48 
of the Core Phase ). Subjects will be administered one of the following, depending on their 
randomization:
Erenumab (70 mg or 140 mg): 70 mg/1mL  syringes. 
Locally  approved oral prophy lactics -dose varies and expenses will be covered b y the 
sponsor .
At the completion of the Core Phase patients that enter the Extension Phase will be administered 
erenumab atthe site(Week 52) and will then be required to have quarterl y study  visits atthe 
siteat which time stud y drug will be administered by  [CONTACT_14523]. Between the quarterl y 
visits patients will have injections of study  drug every  28 day s either 1) administered at site by 
[CONTACT_348181] 2) self -administered at home with do cumented on-
site 
training for correct injection procedures.
The investigator must promote compliance administering the study  treatment exactly  as 
prescribed. There are no temporal restrictions for study  drug administration (e.g., proximity  to 
meals, sleep or activity ). For the comparators, please refer to approved package insert for label 
on dosing and possible temporal restrictions.
All study  treatment assigned will be recorded in the IRT. [COMPANY_001] monitors will reconcile 
treatment assigned versus treatmen t administered and ensure that the information is congruent 
during their monitoring visits.
7 Informed consent procedures
Eligible subjects may  only  be included in the study  after providing (witnessed, where required 
by [CONTACT_6617]), I RB/IEC -approved i nformed consent.
If applicable, in cases where the subject's representative(s) gives consent (if allowed according 
to local requirements), the subject must be informed about the study  to the extent possible given 
his/her understanding. If the subject is ca pable of doing so, he/she must indicate agreement by 
[CONTACT_37249] y signing and dating the written informed consent document.

[COMPANY_001] Confidential Page 40
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Informed consent must be obtained before conducting any study -specific procedures (e.g., all 
of the procedures described in the protoc ol). The process of obtaining informed consent must 
be documented in the subject source documents.
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guidelines and regulatory  requirements and is considered 
appropriate for this study . Any changes to the proposed consent form suggested by [CONTACT_49413] I RB/IEC.
Information about common side effects alread y known about the investig ational drug can be 
found in the prescribing information/package insert/CDS. This information will be included in 
the subject informed consent and should be discussed with the subject during the study  as 
needed. Any new information regarding the safety  profile of the investigational drug that is 
identified will be communicated as appropriate, for example, via an investigator notification or 
an aggregate safet y finding. New information might require an update to the informed consent 
and then must be discussed with the subject.
Women of child- bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study they  must adhere to the contraception requirements.
Male subjects must be informed that if a female partner becomes pregnant while he is enrolled 
in the study , contact [CONTACT_49414].
A copy of the approved version of all consent forms must be provided to [COMPANY_001] after IRB/IEC 
approval.
Subjects might be asked to complete an optional questionnaire to provide feedback on their 
clinical trial experience.
During the COVID -[ADDRESS_432529] the 
informed consent discussion remotely  (e.g. telephone, videoconference). Guidance issued by 
[CONTACT_348182] y 
documented (e.g. the presence of an impartial witness, sign/dating separate ICFs by [CONTACT_348183], etc).
During the COVID -19 pandemic the Investigator should discuss the home -delivery  of study 
drug, and should provide detailed step by [CONTACT_348184]-
administration of study  drug including: 1) the correct handling, 2) self-administration procedure, 
and 3) stora ge of study  drug. This training may be done in person or videoconference or by 
[CONTACT_348185]. This training process needs to be documented 
in the patient’s source documents with the patient’s verbal/e -mail/ or chat function agreement.  
Guidance issued by [CONTACT_157092] y documented (e.g. the presence of an impartial witness, sign/dating separate ICFs 
by [CONTACT_6622], etc.).  Written informed consent 
must be obtained once protocol amendment 2 is approved at the site.

[COMPANY_001] Confidential Page 41
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
8 Visit schedule and assessments
Assessment schedule Table 8 -1and Table 8 -2lists all of the assessments and indicates with an 
“X" when those assessments are performed. All data obtained from these assessments must be 
supported in the subject’s source documentation.
Visit windows for each visit must be completed within +-5 daysfrom Day 1  w ith visits 
occurring every  28 day s asdescribed in Table 8 -1and Table 8 -2.  In addition, visits need to be 
scheduled within the protocol specified visit windows to ensure that drug is administered within 
dosing windows (23 to 33 day
s from previous dose).
Subjects should be seen for all visits/assessments as outlin ed in the assessment schedule or as 
close to the designated day/time as possible. Missed or rescheduled visits should not lead to 
automatic discontinuation. Subjects who prematurely  discontinue the study  for any reason 
should be scheduled for a visit as soon as possible, at which time all of the assessments listed 
for the final visit will be performed. At this final visit, all dispensed investigational product 
should be reconciled, and the adverse event and concomitant medications recorded on the CRF.
Treat ment discontinuation does not imply  study discontinuation. Every  effort should be 
attempted to ensure subjects complete the stud y visits event if treatment is discontinued.
If the COVID -19 pandemic limits or prevents on-site study  visits, alternative methods of 
providing continuing care may  be implemented. Phone calls, virtual contacts (e.g. teleconsult) 
or visits by  [CONTACT_348186]´s home depending on local regulations and capabilitie s, 
can replace on-site study  visits, for the duration of the pandemic until it is safe for the participant 
to visit the site again (see Section 
8.3efficacy , Section 8.4.1 Laboratory evaluatio ns, Section 
8.4.3 Pregnancy , Section 8.5.3  and Section 8.4  Safet y monitoring .

[COMPANY_001] Confidential Page 42
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Table 8-1 Assessment Schedule –Core Phase
Period Screening Open Label Randomized Treatment
Visit Name [CONTACT_348201] 
4Week 
8Week 
12Week 
16Week 
20Week 
24Week 
28Week 
32Week 
36Week 
40Week 
44Week 
48Week 52 / 
Early  Exit10
Days-42 to -28 -28 to -1 Day 1 28 56 84 112 140 168 196 224 252 280 308 336 364
Weeks -6 to -4 -4 to -1 1 4 8 12 16 20 24 28 32 36 40 44 48 52
Informed consent X
Medical history/current medical 
conditionsX
Demography X
Physical Examination1X X X X X X X X X X X X X X X X
Vital signs and body measurements X X X X X X X X X X X X X X X X
Electrocardiogram (ECG) X X X
Pregnancy Test (serum)2X X
Pregnancy test (urine)2X X X X X X X X X X X X X X X
Central blood chemistry - Erenumab X X X X
Central blood chemistry – SoC Oral 
Prophylactics3 X X X3X3X3X3X3X X3X3X3X3X3X3X
Urine Drug Screen X
Columbia -Suicide Severity Rating 
Scale (C -SSRS)[ADDRESS_432530] IRT X X X X X X X X X X X X X X X
Clinical Outcome Assessment(s)6X X X X X X X X X X X X X X X
Patients' Global Impression of 
ChangeX X X X X

[COMPANY_001] Confidential Page 43
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Period Screening Open Label Randomized Treatment
Visit Name [CONTACT_348201] 
4Week 
8Week 
12Week 
16Week 
20Week 
24Week 
28Week 
32Week 
36Week 
40Week 
44Week 
48Week 52 / 
Early  Exit10
Days-42 to -28 -28 to -1 Day 1 28 56 84 112 140 168 196 224 252 280 308 336 364
Weeks -6 to -4 -4 to -1 1 4 8 12 16 20 24 28 32 36 40 44 48 52
Adverse Events9X X X X X X X X X X X X X X
Serious Adverse Events9X X X X X X X X X X X X X X X X
Concomitant medications X X X X X X X X X X X X X X X X
Concomitant therapi[INVESTIGATOR_014] X X X X X X X X X X X X X X X X
Core phase10completion X
XAssessment to be recorded in the clinical database or received electronically from a vendor
1Full exam at Screening, W eek 52.  Height and weight will be measured at full exam. Short physical exam at all other visits.
2Results of pregnancy tests (serum or urine) will be captured as source and not in eCRF.
3For subjects randomized to SoC oral pro phylactics, central blood chemistry must be done at Screening, Treatment, W eek 24, W eek 52. All other visits, central blood 
chemistry to be done as needed for monitoring. Any additional safety measurements, if applicable, should be implemented as pe r label .
4C-SSRS will be the electronic C-SSRS designed for computer administration (web or phone)
5At every monthly study visit, the investigator should assess tolerability to randomized treatment (erenumab or SoC oral prophylactics) and determine if switching is 
appropriate.  At Week 48, this will be the last dose of erenumab for subjects randomized to erenumab (monthly treatment). SoC oral prophylactics will continue to be 
dosed through month [ADDRESS_432531] and SAE collection will be capture d after informed consent is obtained.
10Patients that complete Core Phase visits through W eek 52 may be eligible to enter the Extension Phase. All patients will receive erenu mab during the Extension Phase.

[COMPANY_001] Confidential Page 44
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Table 8-2 Assessment Schedule –Extension Phase
Period Post -Trial Access Open -Label Treatment Period
Visit NameWeek 
52Week 
56Week 
60Week 
64Week 
68Week 
72Week 
76Week 
80Week 
84Week 
88Week 
92Week 
96Week 
100Week [ADDRESS_432532] IRT X X X X X X X X X X X X X X
AEs/ SAEs X X X X X X X X X X X X X X
Con. medications / therapi[INVESTIGATOR_014] X X X X X X X X X X X X X X
Pregnancy test (urine) X X X X X X
Extension Phase 
CompletionX
X Assessment to be recorded in the clinical database or received electronically from a vendor
1Study drug administration visit only .

[COMPANY_001] Confidential Page 45
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
8.[ADDRESS_432533]’s eligibility . Assessments cannot be performed prior to 
signature [CONTACT_28513]. I f the subject does not fulfill all inclusion/exclusion criteria, 
he/she must be documented as a screening failure ( Section
8.1.1). It is permissible to re-screen 
a subject if he/she fails the initial screening criteria. If the subject is re-screened, a new ICF 
must be obtained and re-screening will be documented in the subject's source documents. A 
new subject number will be allocated and the site wil l record data in a new CRF.
8.1.1 Information to be collected on screening failures
Subjects who sign an 
informed consent but fail to enter the Open -Label Treatment Period for 
any reason will be considered a screen failure. The reason for not being started on treatment 
will be entered on the screening phase disposition page and baseline phase completion eCRF 
(as applicable). The demographic information, informed consent, and Inclusion/Exclusion 
pages must also be completed for screen failure subjects. No other da ta will be entered into the 
clinical database for subjects who are screen failures, unless the subject experienced a serious 
adverse event during the screening phase (see SAE section for reporting details). If the subject 
fails to be randomized, the IRT must be notified within [ADDRESS_432534] demographics/other baseline characteristics
Subject demographic and baseline characteristic data will be collected on all subjects. This will 
include age, sex, age, race, ethnicit y, source of patient referral (if applicable), and relevant 
medical history /current medical condition present before signing informed consent, where 
possible. Diagnoses and not sy mptoms will be recorded.
Prior headache characteristics and previous headache medication history , including information 
on the suitability  for migraine proph ylactics and prior migraine proph ylactic treatment failure 
history , will be collected as part of screening and baseline characteristics.
Investigators will have the discretion to record abnormal test findings on the medical history 
eCRF whenever in their judgment the test abnormality  occurred prior to the informed consent 
signature.
8.3 Efficacy
Efficacy  assessments will include:
Migraine day s
Patient study  completion
The timing and frequency  of these assessments are outlined in Table 8-1. Subjects will record 
the efficacy  information using the provided eDiary  platform. To aid in compliance, it is 

[COMPANY_001] Confidential Page 46
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
recommended that the information be completed at the same time every  day and this will be 
pre-defined in the eDiary by [CONTACT_348187]. Retroactive completion will be allowed one day prior 
to the time of completion. Any entries >[ADDRESS_432535] experiences a qualified 
migraine headache (onset, continuation, or recurrence of the migraine headache). A qualified 
migraine headache is defined as a migraine with or without aura, lasting for ≥ [ADDRESS_432536] one of the following criteri a:
1.≥2 of the following pain features: 
Unilateral
Throbbing
Moderate to severe
Exacerbated with exercise/phy sical activity
2.≥1 of the following associated sy mptoms: 
Nausea and/or vomiting
Photophobia and phonophobia
If the subject took a migraine -
specific medication (ie, triptan or ergotamine) during aura, or to 
treat a headache on a calendar day, then it will be counted as a migraine day regardless of the 
duration and pain features/associated s ymptoms.
To further characterize a migraine day , the following information will be collected:
Date and time of start of headache (ie, migraine or non- migraine headache)
Date and time of end of headache
Worst pain severity  per headache
Pain features (eg, one -sided, throbbing, worsens with exercise/phy sical activity )
Symptoms (eg, aura, nausea, vomiting, photophobia, phonophobia , vertigo )
Use of acute headache medications (medication name (from pre- entered list), date and 
time of dosing, number of times taken of each date, number of units taken).
For women of child -bearing potential, start and end dates of monthly  menses 
8.3.2 Appropriateness of efficacy  assessments
The definition of migraine day (Section 8.3.1) is consistent with the diagnostic criteria of 
migraine and probable migraine according to the International Classification of Headache 
(ICHD -3). The monthly  migraine days will be calculated using migraine day data collected 
from the eDiary . Migraine days are commonl y used as a primary  endpoint in pi[INVESTIGATOR_348147] 
(Tfelt -Hansen et
al2012 ) and is consistent with the erenumab clinical development.

[COMPANY_001] Confidential Page 47
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
As the mean change in monthly  migraine day (MMD) however describes a popul ation- based 
measure and given the natural variability in migraine trials often is associated with small effect 
sizes, clinically  an important complementary  information is the proportion of subjects that 
achieve a certain clinical benefit, which is usually  described with achieving at least a 50% 
reduction of migraine days compared to the individual baseline ("50% responder rate"). In 
pi[INVESTIGATOR_6518], 50% (or higher) responder rates are usually  included as secondary  or key 
secondary  outcomes. Given that this trial is not considered a pi[INVESTIGATOR_348148], the 50% reduction was considered more relevant and therefore 
chosen as part of the primary  endpoint. The percentage of patients completing the study 
(retention rates) was selected as part of the composite endpoint based on the long-term data 
from earlier clinical studies (20120255 and 20120296) confirming retention remains high for 
erenumab treated patients at one year (75 -80%) and that efficacy  is continued over time, which
would be clinicall y relevant when compared to available proph ylactic treatment.
 
 
 
 
 
 
 
8.4 Safet y
Safety  assessments are specified below with the as sessment schedule (Table 8-1and Table 8-2) 
detailing when each assessment is to be performed.
For details on AE collection and reporting, refer to AE section
 Section 10.1).
During theCOVID -19 pandemic that limits or prevents on-site study visits, regular phone or virtual 
calls will occur (at the time of every  schedule visit or more frequently if needed) for safety 
monitoring and d iscussion of the participant´s health status until the participant can again visit the 
site.
Table 8
-3 Safety  Assessments
Assessment Specification
Physical examination A com plete physical examination will include the examination of general 
appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, 
heart, abdomen, back, ly mph nodes, extremities, vascular, and 
neurological. If indicated based on medical histor y and/or sy mptoms, rectal, 
external genitalia, breast, and pelvic exams will be performed. A complete 
physical exam will be at Screening, and Week 52
A short phy sical exam will include the examination of general appearance 
and vital signs (blood pressure [ SBP and DBP] and pulse). A short phy sical 
exam will be at all visits starting from Baseline except where a complete 
physical examination is required (see above). 

[COMPANY_001] Confidential Page 48
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Information for all physical examinations must be included in the source 
documentation at the study site. Clinically relevant findings that are present 
prior to signing informed consent must be included in the Medical History 
part of the CRF. Significant findings made after first administration of 
investigational drug which meet the definition of an Adverse Event must be 
recorded on the Adverse Event section of the CRF.
Vital signs Vital signs include BP and pulse measurements. After the patient has been 
sitting for five minutes, with back supported and both feet placed on the 
floor, systolic and diastolic blood pressure will be measured three times 
using an automated validated device, e.g. OMRON, with an appropriately 
sized cuff. The repeat sitting measurements will be made at 1 -2 minute 
intervals and the mean of the three measurements will be u sed. In case the 
cuff sizes available are not large enough for the patient's arm 
circumference, a sphygmomanometer with an appropriately sized cuff may  
be used.
Clinically notable vital signs are defined in Appendix 1 .
Height & weight Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram 
(kg) in indoor clothing, but without shoes) will be measured during full 
physical exams .
Columbia Suicide 
Severity Rating ScaleSee Section 10.2.2
8.4.1 Laboratory  evaluations
A central laboratory  will be used for analy sis of all specimens collected. Details on the 
collections, shipment of samples and reporting of results by [CONTACT_348188].
Clinically  notable laboratory  findings are defined in Section 16.1.
During the 
COVID -19 pandemic that limits or prevents on -site study  visits, or if visits by  [CONTACT_348189] a participant’s home are not feasible ,the collection of samples may be modified by 
[CONTACT_348190] (e.g., local lab collection of samples). 
Urine Drug Screen
Patients will be tested for substances of abuse at initial screening to confirm patient eligibil ity. 
During the study , urine drug tests can be performed at the investigator's discretion based on 
clinical suspi[INVESTIGATOR_2798]. Urine samples will be analyzed by [CONTACT_2237]. If a patient has a 
positive urine drug screen during the study  (except for certain prescribed information), the 
investigator should consider discontinuation from the investigational product.
8.4.2 Electrocardiogram (ECG)
ECGs will be recorded as outlined in the central ECG reading manual. The preferred sequence 
of cardiovascular data colle ction during study  visits is ECG collection first, followed by [CONTACT_166211], and blood sampling. The Fridericia QT correction formula (QTcF) as reported by [CONTACT_348191].
Single [ADDRESS_432537] be collected and archived at the study site.

[COMPANY_001] Confidential Page 49
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Each ECG tracing must be labeled with study  number, patient initials, subject number, date and 
time, and filed in the study  source do cuments. For any ECGs with patient safety  concerns, two 
additional ECGs must be performed to confirm the safet y finding and forwarded to the central 
ECG laboratory  for assessment. Clinically  significant ECG findings pre-dose must be discussed 
with the sponsor before administration of study  treatment. 
Clinically  significant abnormalities must be recorded on the relevant section of the medical 
history /current medical conditions/AE eCRFs as appropriate.
8.4.[ADDRESS_432538] results.
8.4.4 Appropriateness of safety  measurements
The safet y assessments were selected based on the safet y profile of erenumab as reported in the 
development Investigator Brochure, package insert/prescribing information, and are standard 
for this patient population and drug class.
For SoC oral proph ylactics, additional safet y measurements, if applicable, should be 
implemented as per label. 
8.5 Additional assessments
The following additional assessments will be done. The timing and frequency  of these 
assessments are outlined in Table 8-1:
Clinical Outcome Assessments/Patient Reported Outcomes
8.5.1 Clinical Outcome A ssessments (COA s)
Clinical Outcomes Assessments (COAs) will be collected b y subjects using an electronic diary 
(eDiary )/site tablet at various frequencies. The eDiary will collect the following dail y, at home:
Date and time of st art of headache (i.e., migraine or non -migraine headache)
Date and time of end of headache
Worst pain severity  per headache
Pain features (e.g., one -sided, throbbing, worsens with exercise/phy sical activity )

[COMPANY_001] Confidential Page 50
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Symptoms (e.g., aura, nausea, vomiting, photophobia, phonophobia)
Use of acute headache medications (medication name [CONTACT_348202]- entered list, date of 
dosing, dosing and frequency )
The eDiary  will categorize headache events as migraine days or headache days based on the 
definitions below:
Headache Day -any calendar day  in which the subject experiences a qualified headache 
(initial onset, continuation, or recurrence of the headache). A qualified headache is defined 
as the following: 
a qualified migraine headache (including an aura
-only event that i s treated with acute 
migraine -specific medication), or
a qualified non -migraine headache, which is a headache that lasts ≥30 minutes and is 
not qualified as a migraine headache, or
a headache of an y duration for which acute headache treatment is administer ed.
Migraine Day  -See Section 8.3.[ADDRESS_432539] the following patient -reported outcomes (PROs) and questionnaires:
Patients' Global Impression of Change (PGIC)
The site study  staff will train the patient on proper use of the eDiary  (e.g., turning on/off, 
navigation, data transmission, helpdesk, etc.) and completing the questions. The patient will be 
instructed to interact with the eDiary  daily during the Baseline Period and Open -Label 
Treatment Period and to bring the eDiary  to every  study visit. At D ay 1/Treatment, the 
investigator will use the patient's eDiary  to review all data entered during the Baseline Period 
and confirm the relevant inclusion/exclusion criteria. The eDiary  manual should be used to 
locate additional details.

[COMPANY_001] Confidential Page 51
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401

[COMPANY_001] Confidential Page 52
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
[IP_ADDRESS] Patients' Global Impression of Change
The Patients' Global Impression of Change (PGIC) is a global assessment by  [CONTACT_348192]. The PGIC is assessed periodicall y through 
the treatment period and at the end of the treatment period. The PGIC ratings are as follows:
1 = No change (or condition is worse)
2 = Almost the same, hardly  any change at all
3 = A little better, but no noticeable change
4 = Somewhat better, but t he change has not made any  real difference
5 = Moderately  better, and a slight noticeable change
6 = Better, and a definite improvement that has made a real and worthwhile difference
7 = A great deal better, and a considerable difference that has made all the difference

[COMPANY_001] Confidential Page 53
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
[ADDRESS_432540] if, he/she believes that 
continuation would negatively  impact the subject's well -being.
Study  treatment must be discontinued under the following circumstances: 
Subject/guardian decision
Pregnancy
Use of prohibited treatment as per recommendations in the prohibited treatment section

[COMPANY_001] Confidential Page 54
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Any situation in which study  participation might result in a safet y risk to the subject
In addition during the Extension Phase, study  treatment should be discontinued under the 
following circumstances 
Patient is no longer clinically  benefitting from treatment in the opi[INVESTIGATOR_348149], the investigator should make a reasonable effort 
to understand the primary reason for the subject’s premature discontinuation of study treatment 
and record this information.
Subjects who discontinue study  treatment or who decide they do not wish to participate in the 
study  further should NOT be considered withdrawn from the study  UNLESS they  withdraw 
their consent (see withdraw of informed consent section,). Where possible, they should return 
for the assessments indicated in the assessment schedule. If they fail to return for these 
assessments for unknown reasons, every  effort (e.g. telephone, e-mail, letter) should be made 
to contact [CONTACT_423]/pre -designated contact [CONTACT_348193] d in the lost to follow -up section. This 
contact [CONTACT_18616].
If the subject cannot or is unwilling to attend any  visit(s), the site staff should maintain regular 
telephone contact [CONTACT_1155], or with a person pre-designated by [CONTACT_423]. This 
telephone contact [CONTACT_6636].
After study  treatment discontinuation, at a minimum, in abbreviated visits, the following data 
should be collected at site visits or via telephone/email contact:
new / concomitant treatments
adverse events/Serious Adverse Events
The investigator must also contact [CONTACT_37284]’s discontinuation from study  
treatment.
NOTE: Subjects that wish to enter the Extension Phase and receive PTA access to erenumab 
need to remain in the trial and complete all study visits through Week 52 as described in Table 
8-1.The investigator would then assess eligibi lity of the patients as described in Section 3.0.
9.1.2 Discontinuation of study
For patients that will discontinue from the study  they need to complete the Early  Exit Visit /
Week 52 visit at the time of study  discontinuation.
[IP_ADDRESS] Replacement policy
Subjects will not be replaced on study .
9.1.[ADDRESS_432541]:
Does not want to participate in the study  anymore, and

[COMPANY_001] Confidential Page 55
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Does not allow further collection of personal data 
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information. 
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact [CONTACT_5366] -up. 
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table. 
[COMPANY_001] will continue to keep and use collected study  information (including any data resulting 
from the anal ysis of a subject’s samples until their time of withdrawal) according to applicable 
law. 
For US: All biological samples not y et analy zed at the time of withdrawal may still be used for 
further testing/anal ysis in accordance with the terms of this protocol and of the informed consent 
form. 
For EU: All biological samples not yet analyzed at the time of withdrawal will no longer be 
used, unless permitted by [CONTACT_1289]. They  will be stored according to applicable legal 
requirements. 
9.1.[ADDRESS_432542] show "due diligence" by 
[CONTACT_762], e.g. dates of telephone 
calls, registered letters, etc. A subject should not be considered as lost to follow -up until due 
diligence has been completed and until the end of the study .
9.1.5 Early  study termination by  [CONTACT_18620]. This may  include reasons 
related to the benefit/ risk assessment of participating in the study , practical reasons (including 
slow enrollment), or for regulatory  or medical reasons. In taking the decision to terminate, 
[COMPANY_001] will alway s consider the patient welfare and safet y. Should early  termination be 
necessary , 
patients must be seen as soon as possible (provide instruction for contact[CONTACT_348194], when the patient should stop taking drug, when the patient should come for a final visit) 
and treated as a prematurely  withdrawn patient. The investigator may be informed of additional 
proced ures to be followed in order to ensure that adequate consideration is given to the 
protection of the patient’s interests. The investigator or sponsor depending on the local 
regulation will be responsible for informing IRBs/IECs of the early  termination of the trial.

[COMPANY_001] Confidential Page 56
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
9.[ADDRESS_432543]-trial access to erenumab will be offered to the study  participants 
as needed.
10 Safety  monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study . Therefore, an AE may  or may  not be temporally  or causall y associated with the use of a 
medicinal (investigational) product. Adverse event collection will begin at Treatment/Day  1 
(treatment emergent adverse events). Any event prior to Treatment/Day  [ADDRESS_432544] be recorded in the Adverse Events CRF 
under the signs, symptoms or diagnosis associated with them, accomp anied by [CONTACT_131570] (as far as possible) (if the event is serious refer to Section 10.1.2 ):
1.The severit y grade. 
mild: usually  transient in nature and generally  not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
2.its relationship to the study  treatment. If the event is due to lack of efficacy or progression 
of underl ying illness (i.e. progression of the study indication) the assessment of causalit y 
will usually  be ‘Not suspected’. The rationale for this guidance is that the sy mptoms of a 
lack of efficacy  or progression of underly ing illness are not caused by  [CONTACT_6645], they  
happen in spi[INVESTIGATOR_348150]/or both lack of efficacy and progression of 
underly ing disease can only  be evaluated meaningfull y by [CONTACT_49430], not on a 
single subject

[COMPANY_001] Confidential Page 57
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
3.its duration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not r esolved must be reported.
4.whether it constitutes a SAE (see Section 10.1.2 for definition of SAE) and which 
seriousness criteria have been met
5.action taken regarding with study  treatment All adverse events must be treated 
appropriatel y. Treatment may include one or more of the following:
Dose not changed
Dose Reduced/increased
Drug interrupted/withdrawn
6.its outcome 
a.not recovered/not resolved;
b.recovered/resolved;
c.recovered/resolved with sequelae;
d.fatal; or unknown.
Conditio ns that were alread y present at the time of informed consent should be recorded in 
medical history  of the subject. Adverse events (including lab abnormalities that constitute AEs) 
should be described using a diagnosis whenever possible, rather than individ ual underly ing 
signs and symptoms. Adverse event monitoring should be continued for at least [ADDRESS_432545] be followed until its resolution or until it is judged to 
be permanent (e.g. Continuing at the end of the study ), and assessment must be made at each 
visit (or more frequently, if necessary) of an y changes in severity, the suspected relationship to 
the interventions required to treat it, and the outcome.
Information about adverse drug reactions for the investigational drug can be found in the 
prescribing information/package insert/CDS.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:
they induce clinical signs or sy mptoms
they are considered clinically  significant
they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non -typi[INVESTIGATOR_37206]. Alert ranges for laboratory and other test abnormalities are included in 
Section 16.1.

[COMPANY_001] Confidential Page 58
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
10.1.2 Serious adverse events
An SAE is defined as any adverse event [appearance of (or worsening of any pre-existing)] 
undesirable sign(s), symptom(s) or medical conditions(s)) which meets any one of the following 
criteria:
fatal
life-threate ning -Life-threatening in the context of a SAE refers to a reaction in which the 
subject was at risk of death at the time of the reaction; it does not refer to a reaction that 
hypothetically  might have caused death if it were more severe (please refer to the ICH-
E2D Guidelines).
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_1081], unless 
hospi[INVESTIGATOR_062]: 
routine treatm ent or monitoring of the studied indication, not associated with any  
deterioration in condition 
elective or pre -planned treatment for a pre -existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
social reasons and respi[INVESTIGATOR_37207]’s 
general condition
treatment on an emergency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]
is medically  significant, e.g. defined as an event that jeopardizes the subject or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threatening or result in death or hospi[INVESTIGATOR_37208]. Such events should be 
considered as “medicall y significant”. Examples of such 
events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospi[INVESTIGATOR_37209] (please refer to the ICH-
E2D Guidelines). 
All malignant neoplasms will be assessed as serious under “medically  significant” if other 
seriousness criteria are not met.
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred. 
10.1.[ADDRESS_432546] be reported 
to [COMPANY_001] safet y 

[COMPANY_001] Confidential Page 59
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
within [ADDRESS_432547] be reported separatel y as a new event.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the study  treatment, a CMO & PS Department 
associate may urgentl y require further information from the investigator for health authorit y 
reporting. [COMPANY_001] /sponsor may need to issue an Investigator Notifica tion (IN) to inform all 
investigators involved in any study  with the same study  treatment that this SAE has been 
reported.
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/[ADDRESS_432548] be 
reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.
Pregnancy  should be recorded and reported by [CONTACT_37288]  (CMO&PS). Pregnancy  follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the study  treatment and 
any pregnancy  outcome. Any  SAE experienced during pregnancy  must be reported.
10.1.5 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, subject or 
consumer (EMA definition). Misuse refers to situations where the medicinal product is 
intentionally  and inappropriately  used not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the DAR (dose administration record) eCRF irrespective of whether or not associated with an 
AE/SAE and reported to 
Safety  only if associated with an SAE. Misuse or abuse will be 
collected and reported in the safet y database irrespective of it being associated with an AE/SAE 
within 24 h ours of Investigator’s awareness.

[COMPANY_001] Confidential Page 60
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error type Document in Dose 
Administration (D AR) 
eCRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unintentional study 
treatment errorYes Only if associated with 
an AEOnly if associated with 
an SAE
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see the, 
respective sections.
10.[ADDRESS_432549] safety  and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.
The following two categories of abnormalities / adverse events have to be considered during 
the course of the study  (irrespective of whether classified/reported as AE/SAE):
Liver laboratory  triggers, which will require repeated assessments of the abnormal 
laboratory  parameter
Liver events, which will require close observation, follow- up monitoring 
Please refer to Section 16.2 for complete definitions of liver laboratory  triggers and liver events.
Every  liver event defined in Table 16-2should be followed up by [CONTACT_201079], as summarized below. Additio nal details on actions required in case 
of liver events are outlined in Table 16-3. Repeat liver chemistry  tests (ALT, AST, TBL, 
PT/INR, ALP and G -GT) to confirm elevation.
These liver chemistry  repeats will be performed using the central laboratory. I f results will not 
be available from the central laboratory , then the repeats can also be performed at a local 
laboratory  to monitor the safet y of the subject. If a liver event is subsequently  reported, any 
local liver chemistry  tests previously  conducted that are associated with this event should have 
results reported on the unplanned local laboratory  CRF.
If the initial elevation is confirmed, close observation of the subject will be initiated, 
including consideration of treatmen t interruption if deemed appropriate.
Discontinuation of the investigational drug (refer to the Discontinuation of study  treatment 
section), if appropriate
Hospi[INVESTIGATOR_131539]
Causality  assessment of the liver event
Thorough inves tigation of the liver event -
These investigations can include based on investigator’s discretion: serology tests, 
imaging and pathology  assessments, hepatologist’s consultancy ; obtaining more 

[COMPANY_001] Confidential Page 61
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
detailed history  of sy mptoms and prior or concurrent diseases, history  of concomitant 
drug use, exclusion of underly ing liver disease
All follow -up information, and the procedures performed must be recorded as appropriate.
10.2.2 Prospective suicidality assessment
The Columbia -Suicide Severit y Rating Scale (C-SSRS) is a questionnaire that prospectively 
assesses suicidal ideation and suicidal behavior. The C-SSRS will be administered at Screening.
A validated version of the C-SSRS will be used to capture self-reported C-SSRS data via an 
interactive voice response telephone system (eC-SSRS). The eC-SSRS uses a detailed branched 
logic algorithm to perform the C- SSRS subject interview, evaluating each subject’s suicidality 
ideation and behavior in a consistent manner. At the conclusion of each assessment, the 
investigator will receive a detailed eC-SSRS Findings Report via e-mail or fax. If the system 
assesses the subject as having positive suicidal signs, the investigator will be immediately 
notified by  [CONTACT_348195], email and/or via telephone.
If, at any time after screening and/or baseline, the score is “yes” on item 4 or item 5 of the 
suicidal ideation section of the C-SSRS or “yes” on any item of the suicidal behavior section, 
the subject must be referred to a mental health care professional for further assessment and/or 
treatme nt. The decision on whether the study  treatment should be discontinued is to be taken 
by [CONTACT_348196].
In addition, all life-threatening events must be reported as SAEs . For example, if a subject 
answers “ yes” to one of the questions in the suicidal behavior section, an SAE must be reported 
if the event was life-threatening. All events of “Non -Suicidal Self-Injurious Behavior” 
(question also included in the suicidal beha vior section) should be reported as AEs and assigned 
the appropriate severity  grade.
11 Data Collection and Database management
11.1 Data collection
Designated investigator staff will enter the data required by [CONTACT_37290] (eCRF). The eCRFs have been built using fully validated secure web-
enabled software that conforms to [ADDRESS_432550] been trained. Automatic validation programs 
check for data discrepancies in the eCRFs, allow modification and/or verification of the entered 
data b y the investigator staff.
The investigator/designee is responsible for assuring that the data entered into eCRF is complete, 
accurate, and that entry  and updates are performed in a timely  manner. The Investigator must 
certify  that the data entered are complete and accurate. After final database lock, the investigator 
will receive copi[INVESTIGATOR_109002]. All data should 
be recorded, handled and stored in a way that allows its accurate reporting, interpretation and 
verification.

[COMPANY_001] Confidential Page 62
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
11.2 Database management and quality  control
[COMPANY_001] personnel (or designated CRO) will review the data entered by [CONTACT_49432] . Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to 
respond promptly  to queries and to make any  necessary  changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification 
system. Medical history /current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .
Laboratory  samples will be processed centrall y and the results will be sent electronicall y to 
[COMPANY_001]. ECG readings will be processed centrally and the results will be sent electronically to 
[COMPANY_001]. Diary  data will be entered into an electronic diary  by [CONTACT_423]. The sy stem will be 
supplied by a  v endor, who will also mana ge the database. The database will be sent 
electronically  to [COMPANY_001].
Randomization codes and data about all study  treatment (s) dispensed to the subject and all 
dosage changes will be tracked using an Interactive Response Technology (IRT). The system 
will be supplied by a  vendor, who will also manage the database. The data will be sent 
electronically  to [COMPANY_001] at specific timelines.
Each occurrence of a code break via I RT will be reported to the clinical team and monitor. The 
code break functionality  will remain available until study  shut down or upon request of [COMPANY_001].
Once all the necessary  actions have been completed and the database has been declared 
complete and accurate, it will be locked and made available for data analysis. Any changes to 
the d atabase after that time can onl y be made after written agreement b y [COMPANY_001] development 
management.
11.3 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol anddata capture requirements with the investigators and 
their staff. During the study , [COMPANY_001] employ s several methods of ensuring protocol and GCP 
compliance and the quality /integrity  of the sites’ data. The field monitor will visit the site to 
check the completeness of subject records, the accuracy  of data capture / data entry , the 
adherence to the protocol and to Good Clinical Practice, the progress of enrollment, and to 
ensure that study  treatment is being stored, dispensed, and accounted for according to 
specifications. Key study personnel must be available to assist the field monitor during these 
visits. Continuous remote monitoring of each site’s data may be performed by a centralized 
[COMPANY_001] CRA organization. Additionally , a central analy tics organiz ation may  analyze data & 
identify  risks & trends for site operational parameters, and provide reports to [COMPANY_001] clinical 
teams to assist with trial oversight.
The investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_348151]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 

[COMPANY_001] Confidential Page 63
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
assessments. All information on CRFs must be traceable to these source documents in the 
subject’s file. The investigator must also keep the original informed consent form signed by [CONTACT_1560] (a signed cop y is given to the subject).
The in vestigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry . [COMPANY_001] monitoring standards require full 
verification for the presence of informed consent, adherence to the in clusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variables. Additional 
checks of the consistency  of the source data with the CRFs are performed according to the 
study -specific monitoring plan. No information in source documents about the identity  of the 
subjects will be disclosed.
12 Data analy sis and statistical methods
Any data analy sis carried out independently  by [CONTACT_85689].
The core ph ase and extension phase data will be analy zed separately .
12.1 Analysis sets
The Full Analysis Set (FAS) comprises all subjects to whom study treatment has been assigned 
by [CONTACT_17628]. According to the intent to treat principle, subjects will be analyzed according 
to the treatment and stratum they  have been assigned to during the randomization procedure.
The Safet y Set includes all subjects who received at least one dose of study treatment. Subjects 
will be anal yzed according to the stud y treatment received, where treatment received is defined 
as the randomized/assigned treatment if the patient took at least one dose of that treatment or 
the first treatment received if the randomized/assigned treatment was never received. Open label 
extension phase analysis set will include subjects who consented to enter Extension Phase and 
who have taken at least one dose of erenumab in Extension Phase .
12.[ADDRESS_432551] demographics and other baseline characteristics
Demographic variables and other baseline characteristics including previous migraine 
treatments will be summarized for FAS. Descriptive statistics (mean, median, standard 
deviation, minimum, and maximum) will be presented for continuous variables for each 
treatment group and for all participants (total). The number and percentage of participants in 
each category  will be presented for categorical variables for each treatment group and all 
participants 
(total). In addition, all relevant medical history  will be summarized following the 
same strategy .
12.[ADDRESS_432552] deviation, median, 25th and 
75th percentiles, minimum, and maximum will be presented.
A data listing and a summary  of the investigational drug (erenumab or active comparator) 
administered will be provided. Unless otherwise specified, patients assigned to 70mg or 140

[COMPANY_001] Confidential Page 64
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
mg erenumab dose will be analy zed together under one treatment arm erenumab. The analy sis 
by [CONTACT_348197]. 
Concomitant medications and significant non-drug therapi[INVESTIGATOR_49344] (ATC) classification sy stem, by  [CONTACT_1570].
A data listing and summary  of rescue medications will be provided by  [CONTACT_1570].
12.4 Analysis of the primary  endpoint(s)
The primary  aim of the study  is to evaluate the effect of erenumab vs SoC oral proph ylactic
medications on the net benefit, a measure of sustained long -term benefit in these two treatment 
paradigms of migraine prophy lactic agents.
12.4.1 Definition of primary  endpoint(s)
The primary  endpoint of the study  is the proportion of subjects achieving net benefit, defined 
as completion of one year on the initial treatment AND achieving at least a 50% reduction from 
baseline in monthly  migraine day s in the last month (month 12).
12.4.2 Statistical model, hypothesis, and method of analy sis
The primary anal yses will compare the proportio n of subjects in FAS who achieve a net benefit 
(defined in previous section) between erenumab vs SoC oral prophy lactic medications .
To be tested is the null hypothesis that net benefit odds ratio = 1, versus the alternative 
hypothesis: net benefit odds rat io ≠ 1.
A Cochran -Mantel -Haenszel (CMH) test stratified by  [CONTACT_348198] (1 
vs. 2) will be used under a 2-sided significance level of 0.[ADDRESS_432553], and the estimated odds ratio 
between erenumab and active comparator, as well as its 95% confidence interval, will also be 
reported.
The details on primary  and supplementary  estimand will be provided in estimand charter or 
statistical analy sis plan (SAP).
12.4.3 Handling of missing values/censoring/discontinuations
Subjects with missing monthly  migraine day data at month 12 of treatment, and subjects that 
discontinue initial treatment prior to month 12 will be imputed as non-responders (not achieving 
a net benefit).
12.4.4 Sensitivity and Supportive analy ses
The sensitivity  and supportive anal ysis will be detailed in SAP.

[COMPANY_001] Confidential Page 65
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
12.5 Analysis of secondary  endpoints
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s)
Proportion of subjects completing the treatment period at month 12 on the initially 
assigned 
treatment
This variable will anal yzed same as that of the primary  endpoint.
Global satisfaction as measured by [CONTACT_348199] 12 for subjects completing 
treatment period on initially assigned treatment
Patient will be considered as responder if PGI-I score is 5, 6, or 7. Proportion of responders 
based on PGI -I score at month 12 will be analyzed same as that of the primary  endpoint.
Cumulative average change from baseline on the monthly migraine days during the 
treatment period for subjects on the initially assigned treatment (month 1-12)
The average of monthly  migraine days will be obtained cumulatively  at each month across 12 
months (e.g. at month 2 the average will be based on data from month 1 and 2; at month 3 the 
average will be based on month 1 to 3 and so on). The cumulative average change from baseline 
on the monthly  migraine days will be derived using difference between cumulative average at 
each month and baseline monthly  migraine days. The change from baseline will be analy zed 
using a linear mixed effects model including treatment group, baseline value, stratification 
factor(s), scheduled visit, and the interaction of treatment group with scheduled visit.
12.5.2 Safety  endpoints
For all safet y analyses, the safet y set will be used. All listings and tables will be presented by 
[CONTACT_1570] .
Safety  summaries (tables, figures) include only data from the on-treatment period with the 
exception of baseline data which will also be summarized where appropriate (e.g. change f rom 
baseline summaries). In addition, a separate summary  for death including on treatment and post 
treatment deaths will be provided. In particular, summary  tables for adverse events (AEs) will 
summarize only on-treatment events, with a start date during the on-treatment period 
(treatment -emergent 
AEs).
The on-treatment period lasts from the date of first administration of study  treatment to [ADDRESS_432554].
The number (and percentage) of subjects with treatment -
emergent adverse events (events 
started after t he first dose of study  medication) will be summarized in the following way s:
by [CONTACT_3148], primary  system organ class and preferred term.
by [CONTACT_3148], primary  system organ class, preferred term and maximum severity .
by [CONTACT_3148], Standardized MedDRA Query (SMQ) and preferred term

[COMPANY_001] Confidential Page 66
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Separate summaries will be provided for study  medication related adverse events, death, serious 
adverse events, other significant adverse events leading to discontinuation and adverse events 
leading to dose adjustment.
A subject with multiple adverse events within a primary  system organ class is only counted 
once towards the total of the primary  system organ class.
Vital signs
All vital signs data will be listed by [CONTACT_1570], subject, and visit and if ranges are available, 
abnormalities will be flagged. Summary  statistics will be provided by  [CONTACT_3148].
12-lead ECG
All ECG data will be listed by [CONTACT_1570], subject and visit/time, abnormalities will be 
flagged. Summary  statistics will be provided by  [CONTACT_3148].
Clinical laboratory  evaluations
All laboratory  data will be listed by  [CONTACT_1570], subject, and visit and if normal ranges are 
available abnormalities will be flagged. Summary  statistics will be provided by [CONTACT_3148]. Shift 
tables using the low/normal/high/ (low and high) classification will be used to compare baseline 
to the worst on -treatment value.
 
12.5.3 Pharmacokinetics
Not applicable.
12.5.4 DNA
Not applicable.
12.5.5 Biomarkers
Not applicable.
12.5.6 PK/PD relationships
Not applicable.

[COMPANY_001] Confidential Page 67
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
 
 
 
12.7 Interim analy ses
Not Applicable.
12.8 Sam ple size calculation
12.8.1 Primary  endpoint(s)
The sample size calculation is based on the primary  variable, rate of net benefit. The details of 
hypothesis testing are described in Section 12.4.2.
A 2-sided test with significanc e level 0.05, and a 2:1 randomization ratio are considered. A 
sample size of 591 (394 erenumab arm; 197 control arm) is required to achieve 90% power to 
reject the odds ratio of 1 set by [CONTACT_348200]  2, and success 
rate in control arm is 0.18.
An odds ratio of 2 and control rate of 0.18 is based on more conservative assumptions for rate 
of net benefit than observed previousl y (for erenumab in studies [STUDY_ID_REMOVED], [STUDY_ID_REMOVED], 
and oral proph ylactic sin Hepp et
al2017, Shei et al 2015), resulting in a rate difference of 12%. 
Sample size calculations were done using PASS [ADDRESS_432555].
13 Ethical considerations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations (includi ng European Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declaration of Helsinki.
In the US, [COMPANY_010] will be the sponsor and all responsibilities for the conduct of this clinical 
study  will be transferred to [COMPANY_001]. Inall other countries, [COMPANY_001] will be the sponsor and 
maintain all responsibilities for the conduct of the clinical study .
13.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favora ble opi[INVESTIGATOR_18548]/Independent Ethics Committee (I RB/IEC) for the trial protocol, 
written informed consent form, consent form updates, subject recruitment procedures (e.g., 
advertisements) and any other written information to be provided to subjects. Prior to study 
start, the investigator is required to sign a protocol signature [CONTACT_5389]/her agreement 

[COMPANY_001] Confidential Page 68
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
to conduct the study  in accordance with these documents and all of the instructions and 
procedures found in this proto col and to give access to all relevant data and records to [COMPANY_001] 
monitors, auditors, [COMPANY_001] Quality Assurance representatives, designated agents of [COMPANY_001], 
IRBs/IECs, and regulatory  authorities as required. If an inspection of the clinical site is 
requested by a regulatory authority , the investigator must inform [COMPANY_001] immediately  that this 
request has been made.
13.[ADDRESS_432556]. In addition, after study  completion (defined as last patient last visit) 
and finalization of the study report the results of this trial will be submitted for publication and 
posted in a publicly  accessible database of clinical trial results, such as the [COMPANY_001] clinical trial 
results website and all required Health Authority  websites (e.g. Clinicaltrials.gov, EudraCT 
etc.) .
An initial study  report will be prepared and finalized for all data from the Core Phase . A second 
and study report will be prepared for the Extension Phase after all patients have completed their 
respective last visit (L PLV) of the Extension Phase .
For details on the [COMPANY_001] publication policy  including authorship criteria, please refer to the 
[COMPANY_001] publica tion policy training materials that were provided to you at the trial investigator 
meetings .
13.[ADDRESS_432557] Quality  Management System (QMS) that includes all activities 
involved in quality  assurance and qualit y control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and I CH Guidelines.
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protoc ols and internal SOPs, and are performed according to written [COMPANY_001] processes
[ADDRESS_432558] any 
additional procedures for any purpose involving any investigational drugs under the protocol, 
other than the purpose of the study . If despi[INVESTIGATOR_131313], data, information, 
observation would be incidentally  collected, the investigator shall immediately  disclose it to 
[COMPANY_001] and not use it for any purpose other than the study , except for the appropriate 
monitoring on study  participants.

[COMPANY_001] Confidential Page 69
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_18686] B/IEC and health authorities, where required, it cannot be implemented.
14.[ADDRESS_432559] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to 
implementation.
Only  amendments that are required for subject safet y may be implemented immediately 
provided the health authorities are subsequently  notified by [CONTACT_37306]/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate actio n required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should 
be notified of this action and the IRB/IEC at the study  site should be informed according to 
local regulations.

[COMPANY_001] Confidential Page 70
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
[ADDRESS_432560]
(2017) Global, regional, and national incidence, prevalence, and years lived with disability  for 
328 diseases and injuries for 195 countries, 1990 -2016: a sy stematic anal ysis for the Global 
Burden of Disease Study  2016. L ancet p. 1211- 1259.
Ashina M, Dodick D, Goadsby  [CONTACT_33263], et al (2017) Erenumab (AMG 334) in epi[INVESTIGATOR_17730]: 
Interim anal ysis of an ongoing open -
label stud y. Neurology  p. 1237-1243.
Ashina M, Tepper S, Brandes JL , et al (2017) Effi cacy of erenumab in chronic migraine 
patients with prior prophy lactic treatment failure: Subgroup anal ysis of the Phase 2, 
randomised, double -blind, placebo -controlled study . Cephalalgia. 2017;37:326
-328. Poster 
PO-01-180 presented at IHS 2017. 
 
 
Blumenfeld AM, Bloudek L M, Becker WJ, et al (2013) Patterns of use and reasons for 
discontinuation of prophylactic medications for epi[INVESTIGATOR_33213]: 
results from the second international burden of migraine stud y (IBMS -II). Headache p. 644 -
55.
Brande s JL, Diener H, Dolezil D, et al (2017) Chronic Migraine Treatment with Erenumab: 
Responder Rates. Headache. 2017; 57(S3): 113 -226. Poster PS33 presented at AHS 2017.
 
 
Data on File, [COMPANY_010]; Integrated Summary  of Safety  [IP_ADDRESS] AMG334
Dodick DW, Ashina M, Brandes J L, et al (2018) ARISE: A Phase [ADDRESS_432561]  (2006) Calcitonin gene -related peptide (CGRP) and migraine. Headache p. S3-8.
Goadsb y PJ, Paemeleire K, Broessner G, et al (2017) Efficacy of erenumab in subjects with 
epi[INVESTIGATOR_348152](s). Cephalalgia. 2017;37(1S):[ADDRESS_432562] OC -MC-002 presented at IHS 2017. 
Goadsb y PJ, Reuter U, Hallström Y, et al (2017) A Controlled Trial of Erenumab for Epi[INVESTIGATOR_348153]. N. Engl. J. Med. p. 2123 -2132.
Gooriah R, Nimeri R, Ahmed F (2015) Evidence -Based Treatments for Adults with Migraine. 
Pain Res Treat p. 629382.
Hepp Z, Dodick DW, Varon SF, et al (2017) Persistence and switching patterns of oral 
migraine proph ylactic medications among patients with chronic migraine: A retrospective 
claims anal ysis. Cephalalgia p. 470 -485.

[COMPANY_001] Confidential Page 71
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Hepp Z, Rosen NL, Gillard PG, et al (2016) Comparative effectiveness of 
onabotulinumtoxinA versus oral migraine proph ylactic medications on headache -related 
resource utilization in the management of chronic migraine: Retrospective anal ysis of a US -
based insurance claims database. Cephalalgia p. 862-74.
Reuter U, Goadsb y P, Lanteri -Minet M (2018) Efficacy  and Safet y of erenumab in epi[INVESTIGATOR_348154] 2
-4 prior preventive treatment failures: Results from the Phase 3b 
LIBERTY Stud y. Poster 009 presented at AAN 2018..
Reuter U, Goadsb y P, Lanteri -Minet M, et al (2018) Efficacy  and safet y of erenumab in 
epi[INVESTIGATOR_348155] 2–4 prior preventive treatment failures: Results from the 
Phase 3b LIBERTY study. Presented at AAN 2018.
Shei A, Woolley  JM, Desai PR, et al (2015) Description of prophy lactic drug utilization 
patterns in migraine patients. Value in Health p. A285.
Sun H, Dodick DW, Silberstein S, et al (2016) Safety  and efficacy  of AMG 334 for 
prevention of epi[INVESTIGATOR_17730]: a randomised, double- blind, placebo -controlled, phase 2 
trial. Lancet Neurol p. 382 -90.
Tepper S, Ashina M, Reuter U, et al (2017) Safet y and efficacy  of erenu mab for preventive 
treatment of chronic migraine: a randomised, double- blind, placebo -controlled phase 2 trial. 
Lancet Neurol p. 425 -434.
Tepper SJ, Diener H, Ashina M, et al (2017) Efficacy  of erenumab for the treatment of 
patients with chronic migraine in presence of medication overuse. Headache. 
2017;57(S3):113 -226. Poster PS32 presented at AHS 2017. 
Tfelt -Hansen P, Pascual J, Ramadan N, et al (2012) Guidelines for controlled trials of drugs in 
migraine: third edition. A guide for investigators. Cephalalgia p. 6-38.
Wang X, Yue TL, Barone FC, et al (1995) Discovery  of adrenomedullin in rat ischemic cortex 
and evidence for its role in exacerbating focal brain ischemic damage. Proc. Natl. Acad. Sci. 
U.S.A. p. [ZIP_CODE]-4.
 
Zimmermann U, Fischer JA, Frei K, et al (1996) Identification of adrenomedullin receptors in 
cultured rat astrocy tes and in neuroblastboma x glioma hy brid c ells (NG108 -15). Brain Res. p. 
238-45.

[COMPANY_001] Confidential Page 72
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
16 Appendices
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs
Table 16-1 Clinically  Notable Laboratory  Values
Laboratory Variable Gender (M/F/Both) Standard Units SI Units
LIVER FUNCTION A ND RELA TED VA RIABLES
SGOT (AST) F >93 U/L >93 U/L
SGOT (AST) M >111 U/L >111 U/L
SGPT (ALT) F >90 U/L >90 U/L
SGPT (ALT) M >123 U/L >123 U/L
Total bilirubin Both >3.6 mg/dL >63 mmol/L
Alkaline Phosphatase F >832 U/L >832 U/L
Alkaline Phosphatase M >1032 U/L >1032 U/L

[COMPANY_001] Confidential Page 73
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
16.2 Appendix 2: Liver event and Laboratory  trigger Definitions and 
Follow -up Requirements
Table 16-2 Liver Event and Laboratory  Trigger Definitions
Definition/ threshold
LIVER LABORATORY TRIGGERS
[ADDRESS_432563] < ALT / AST £ [ADDRESS_432564]
·1.[ADDRESS_432565] < TBL £ [ADDRESS_432566]
LIVER EVENTS
ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone pathology)
TBL > 2 × ULN (in the absence of known Gilbert 
syndrome)
ALT or AST > 3 × ULN and INR > 1.5
Potential Hy’s Law cases (defined as ALT or AST > 3 × 
ULN and TBL > 2 × ULN [mainly conjugated fraction] 
without notable increase in ALP to > 2 × ULN)
Any clinical event of jaundice (or equivalent term)
ALT or AST > 3 × ULN accompanied by (general) 
malaise, fatigue, abdominal pain, nausea, or vomiting, or 
rash with eosinop hilia
Any adverse event potentially indicative of a liver toxicity*
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -
related conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver 
neoplasms
TBL: total bilirubin; ULN: upper limit of normal
Note: INR (Interna tional Normalized Ratio) me asurements are not collected as part of routine lab 
assessments.  If a patient has a liver event please consider to collect an INR to aid in assessing 
severit y.

[COMPANY_001] Confidential Page 74
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Table 16-3 Follo w Up Requirements for Liver Events and Laboratory  Triggers
Criteria Actions required Follow -up monitoring
Potential Hy’s Law 
caseaDiscontinue the study treatment 
immediately
Hospi[INVESTIGATOR_18552], if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
ALT or A ST
> 8 × ULN
Discontinue the study treatment 
immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
> 3 × ULN and 
INR > 1.5Discontinue the study treatment 
immediately
Hospi[INVESTIGATOR_18552], if clinically appropriate
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
> 5 to ≤ 8 × ULN
Repeat LFT within 48 hours
If elevation persists, continue follow -
up monitoring
If elevation persists for more than 2 
weeks, discontinue the study drug
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at inve stigator 
discretion)
> 3 × ULN 
accompanied by 
[CONTACT_18688] Discontinue the study treatment 
immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at i nvestigator 
discretion)
> 3 to ≤ 5 × ULN 
(patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observation of the patientInvestigator discretion
Monitor LFT within 1 to 4 
weeks
ALP (isolated)

[COMPANY_001] Confidential Page 75
Amended Protocol Version 02 (Clean) Protocol No. CAMG334A2401
Criteria Actions required Follow -up monitoring
> 2 × ULN (in the 
absence of known 
bone pathology)Repeat LFT within 48 hours
If elevation persists, establish 
causality
Complete liver CRFInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
TBL (isolated)
> 2 × ULN (in the 
absence of known 
Gilbert syndrome)Repeat LFT within 48 hours
If elevation persists, discontinue the 
study drug immediately
Hospi[INVESTIGATOR_18553]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
Test for hemoly sis (e.g., 
reticulocytes, haptoglobin, 
unconjugated [indirect] 
bilirubin)
> 1.5 to ≤ 2 × ULN 
(patient is 
asymptomatic)Repeat LFT within the next week
If elevation is confirmed, initiate close 
observation of the patientInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
Jaundice
Discontinue the study treatment 
immediately
Hospi[INVESTIGATOR_18554]
Establish causality
Complete liver CRFALT, AST, TBL, Alb, PT/INR, 
ALP and γGT until resolutionc
(frequency at investigator 
discretion)
Any AE potentially 
indicative of a liver 
toxicity*Consider study treatment interruption 
or discontinuation
Hospi[INVESTIGATOR_6549]
Establish causality
Complete liver CRFInvestigator discretion
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × ULN
b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia
cResolution is defined as an outco me of one of the following: (1) return to baseline values, (2) stable 
values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level 
after a maximum of 6 months, (4) liver transplantation, and (5) death.
